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Abstract
The structural similarity of the Acetylcholine Binding Protein (AChBP) from 
Lymnaea stagnalis to the extracellular ligand binding domain of Ligand Gated Ion 
Channel (LGIC) receptors suggests that the AChBP could be used to mimic cys- 
loop ligand-gated ion channel (LGIC) receptors. An LGIC mimic could be used 
as a sensor molecule in a range of biotechnology applications including high 
throughput drug screening as well as in vivo and in vitro sensing of biologically 
active compounds. It could also be used as a lead molecule for engineering 
novel proteins with binding characteristics similar to non-acetylcholine receptor 
LGIC’s. The soluble AChBP is easily expressed and purified and can be 
produced in reasonably large amounts. This thesis explores the potential for 
using the AChBP and related proteins as biosensors by evaluating their action on 
three key medium and high throughput systems: Scintillation Proximity Assay 
(SPA), Surface Plasmon Resonance (SPR), and Microcantilevers (MC). As a 
preliminary step to developing a 5-HT3R-ligand binding protein, by altering the 
ligand specificity of the AChBP, the interaction of 5-HT3R ligands with the AChBP 
is also evaluated. The work presented in this thesis contributes to improved 
methods of drug design and testing, and to a better understanding of LGIC 
structure.
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Chapter 1: Introduction.
1.1 Ion Channels and Communication between Cells.
Living cells are surrounded by membranes. These membranes must be 
flexible, self-sealing, and selectively permeable, to allow for movement, cell 
replication, and interaction of the cell with its environment [1], Selective 
permeability must also allow for molecular communication between cells in order 
to permit cooperation in multi-cellular organisms. In more complex organisms, 
one cell can regulate the physiology of another through the release of peptides, 
proteins or small ligands.
This ability to regulate, and be regulated by, other cells, frequently 
requires the release of a molecule (a ligand), or group of molecules, capable of 
interacting with proteins on the target cell. The system thus involves release of a 
ligand and its subsequent interaction with a receptor protein. Receptor systems 
are extremely diverse, often complex and always well regulated. Ligand Gated 
ion channel systems are conceptually simple in mechanism; a messenger 
molecule (ligand) from the first cell interacts with a channel protein (receptor) on 
the second cell. The ligand induces or stabilizes an open channel conformation 
in the receptor protein that allows an inward or outward movement of ions.
The ability of ions to carry a charge (thus altering the electrical potential of 
a cell) and to bind and regulate intracellular proteins and nucleic acids makes 
them ideal molecules for inducing physiological changes in cells; thus much of 
the communication between cells is carried out via “ligand-gated” ion channels, 
also known as “ionotropic receptors.” Ion channel mediated cell-cell 
communication is fast and therefore well suited to coordinating cellular activity in 
the nervous systems of complex organisms. Ion channels are typically divided 
into ligand-gated and voltage gated. This thesis focuses on the pentameric cys- 
loop superfamily of ligand-gated ion channel proteins (LGIC). Other LGIC
2families include NMDA-type, kainate-type, and AMPA-type tetrameric glutamate- 
gated cation channels, and trimeric ATP-gated channels [2].
1.2 The cys-loop Ligand Gated Ion Channel (LGIC) Superfamily.
The cys-loop LGIC superfamily of receptors are typified by a characteristic 
disulfide bond between two conserved cysteine residues 13 amino acids apart in 
the primary sequence of all subunits. Mutation of these cysteines and elimination 
of this disulfide bond renders the protein non-functional. Cys-loop LGIC proteins 
display a pentameric quaternary structure and can be either homomeric or 
heteromeric (figure 1.1). Individual subunits are characterized by a large 
extracellular amino-terminal domain and four transmembrane (TM) regions (M1, 
M2, M3, and M4). The extracellular domain is dominated by a large pre-M1, NH3 
domain, a small M2-M3 region and a few C-terminal residues. The intracellular 
domain contains a small M1-M2 region as well as a larger M3-M4 region.
3Figure 1.1: Schematic of Cys-loop LGIC. A: Side views of single subunit (the other four subunits 
are omitted for clarity). B, C, D: Side and top (outside cell) views of the pentamer. In a 
homomeric receptor, each of the five subunits forming the pentamer are identical; in a heteromer, 
the pentamers are formed of more than one different subunit type, but the overall structure 
remains similar. Arrows in C and D indicate potential ligand-binding sites. See text for further 
explanation.
1.3 Neurotransmitter Binding Site of LGIC's.
The agonist binding site in cys-loop receptors is located at the interface 
between the extracellular amino-terminal domains of two adjacent subunits. Five 
potential binding sites exist in the pentameric receptor with each subunit forming 
an interface with two other subunits. In homomeric receptors all 5 interfaces 
likely function as agonist binding sites. In heteromeric receptors 2-3 agonist 
binding sites are typical. The remaining interfaces may function as binding sites 
for allosteric modulators in some receptors. Binding sites are composed of six 
“loops” of amino acids commonly referred to as A-F (Figure 1.2). Each subunit 
contributes three loops on each of its two interfaces with loops A-C located on 
one interface (the + face) and D-F located on the other interface (the -  face).
Figure 1.2: Principal Binding Loops of LGIC Receptors. Left: The relative orientation of the 
binding domains (NH3-terminals) of two LGIC subunits. Middle and right: the plus (+) and minus (- 
) faces (respectively), separated horizontally (i.e. expanded), with their corresponding loops 
labelled. A, B, and C loops are labelled twice in order to clarify their positions. The ligand inserts 
in the vicinity of the arrow, partly under the C-loop, and against the B loop and possibly the A-loop 
on the plus face and probably the D, E, and possibly F loops on the minus face. Protein Data 
Bank file 1I9B (AChBP [3]) and DeepView Swiss Pdb Viewer version 3.7 were used to create this 
figure.
The key binding site regions of Cys-loop LGIC’s were identified by affinity 
labelling studies of the muscle nicotinic acetylcholine receptor, the prototypical 
cys-loop LGIC [4], Structurally homologous binding loops have been identified in 
all members of the cys-loop LGIC superfamily. The specific involvement of 
particular amino acids within the loops has been investigated using a multitude of 
techniques including affinity labelling, alanine scanning mutagenesis, substituted- 
cysteine accessibility method (SCAM), and others. In addition to binding site 
structures, the quaternary structure of the nicotinic acetylcholine receptor has 
also been derived from electron diffraction studies of nicotinic receptors obtained 
from the torpedo electric fish [5]. The most current and detailed model of the 
torpedo nAChR is shown in Figure 1.3. An excellent review of binding site 
structure of the prototypical nAChR can be found in Hogg et al [4],
5T rans- 
Mam crane 
<TM>
B.
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Figure 1.3: Torpedo nicotinic acetylcholine receptor structure. A, B: Ribbon and atomic 
structures, as viewed from side. C, D: Ribbon and atomic structures, as viewed from top (outside 
of cell). Protein Data Bank (PDB) file 2BG9 [5], images created using the DeepView/ Swiss Pdb 
Viewer 3.7.
61.4 Cys-loop LGIC Superfamily Members.
Members of the Cys-loop LGIC superfamily are typically distinguished 
from one another on the basis of their selectivity for a particular endogenous 
agonist (figure 1.4). LGIC’s selective for nicotine and acetylcholine (Ach), y- 
aminobutyric acid (GABA), serotonin (5-HT), and glycine have been identified. 
These ion channel receptors are commonly referred to as nicotinic acetylcholine 
receptors (nAChR’s), y-aminobutyric acid (GABA) receptors, serotonin receptors, 
and glycine receptors. Multiple subtypes of each receptor class can be 
distinguished based on different subunit compositions that produce distinct 
pharmacological profiles. The nicotinic acetylcholine class is divided broadly into 
muscle and neuronal types and the GABA receptor into types A and C.
Members of this family also differ in ion selectivity. The acetylcholine 
receptors and the serotonin receptors (nAChR’s, 5-HT3R’s) are cation selective 
channels that conduct K+ Na+ and Ca+ ions. The GABAaR, GABACR and GlyR’s 
are anion selective channels that conduct primarily Cl" ions. On post-synaptic 
membranes, nAChR’s and 5-HT3R’s are excitatory and GABAR’s and GlyR’s are 
inhibitory. Several other, more obscure, members have recently been tentatively 
added to the superfamily [2]: three Ach-gated Cl" channels from Lymnaea 
stagnalis, GABA-gated cation channel EXP-1 R, a Zn2+ activated cation channel 
receptor (ZACR, Drosophila me/anogastereye), two avermectin-sensitive 
glutamate-gated Cl" channel subunits (GluCIR, in Caenorhabditis e/egans), and 
purported homologous ancestor receptors in prokaryotes [2],
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Figure 1.4: Structures of endogenous agonists for known Cys-loop LGIC. Acetylcholine and 
serotonin are the primary neurotransmitters for excitatory nAChR’s and 5-HT3R’s, respectively. 
Nicotine is a partial agonist at nAChR’s. Inhibitory neurotransmitters glycine and GABA are also 
shown, as well as histamine and glutamate, which activate newly discovered LGIC.
1.5 Cys-loop LGIC physiological implications.
Cys-loop receptors are apparently involved in many physiological processes 
including learning and memory, regulation of blood flow, fluid balance, gastric 
motility, appetite control, and pain [2]. Multiple disease states are thought to 
involve LGIC's including Parkinson’s disease (PD), schizophrenia, Alzheimer’s 
disease (AD) [6-8], autism spectrum disorders [9], attention deficit- hyperactivity 
disorder (ADHD) [6], and nicotine (cigarette smoking) and alcohol addiction [10].
8Despite enormous efforts on the part of a large number of researchers, the 
precise role of LGIC receptors in these many of these disorders remains unclear.
As important receptors implicated in human disease, the cys-loop LGIC 
superfamily of proteins present attractive drug targets. Antagonists, agonists and 
allosteric modulators are all potentially useful therapeutic agents. For example 
transdermal nicotine has been shown to increase attention in AD and ADHD 
patients, and to act on the amygdalae and hippocampus in rat models [6], 
Benzodiazepines are commonly used to treat seizure disorders by increasing 
activity of GABA receptors in the central nervous system (CNS) [2], Serotonin 
antagonists are used to treat chemotherapy induced emesis and nicotinic 
receptor modulators such as galanthamine are being tested as cognitive 
enhancers in AD patients. Steroids and anaesthetics are also thought to alter 
LGIC receptor function. An incomplete knowledge of the specific receptor type 
and subtypes involved in particular disease states presents problems in 
developing therapeutic approaches to neurological disorders involving LGIC 
receptors. This type of evaluation requires subtype selective drugs that are often 
unavailable. The issue is complicated by the sometimes broad selectivity of 
LGIC receptors by even endogenous agonists. For example it is known that 
nAChR’s are modulated by serotonin. This “crosstalk” between receptors makes 
it difficult to identify which neurotransmitter is involved.
Developing more subtype selective compounds is hindered by an 
incomplete knowledge of the drug/receptor interaction at the molecular level and 
the inability to rapidly evaluate drug candidates on multiple receptors subtypes.
1.6 Serotonin type 3 receptor (5-HT3R) subtypes.
The serotonin type 3 receptor (5-HT3R) was first discovered in 1957 by 
Gaddum and Picarelli who observed the effects of serotonin on guinea pig ileum 
[11]. Originally named the “M receptor” this discovery represented the first 
identification of a receptor for serotonin. In 1989, [12] this receptor was
9determined to be a LGIC and was re-named the 5-HT type 3 receptor. Other 
serotonin receptors including types 1, 2 and 4 are not members of the LGIC 
receptor family but are considered “metabotropic” or G-protein coupled receptors. 
Genes codling for A, B, C and E subunits of the Serotonin type 3 receptor have 
been identified [13], [14]. A gene coding for a D subunit has also been identified 
but lacks the amino terminal (extracellular) region. The pharmacology of 5- 
HT3Rs was quickly found to vary between species and evidence for different 
subtypes within a single species was first noted by Bonhaus et al in 1993 who 
observed differences between responses in mouse ileum and cortex [15]. Early 
data suggested that 5HT3R subunit A formed homomeric receptors and this was 
thought to be the predominant subtype in both central and peripheral tissues.
With the cloning of the B subunit in 1999 [16] it became clear the 5-HT3Rs also 
express heteromeric 3A-3B receptors; this finding was assumed to account for 
the findings of Bonhaus [15], since the heteromeric 3A-3B receptors were found 
in the ileum, while homomeric 3A receptors were found in the cortex. The 
precise stoichiometry of the heteromeric receptors is unknown but has been 
postulated that AB receptors are composed of two A subunits and three 3B 
subunits. Ligands that could distinguish between different subtypes were 
unavailable until the discovery of picrotoxin in 2003 [17].
As recently as 2003, Van Hooft [18] argued that there may be only 
homomeric 3A receptors in the central nervous system (CNS). In fact, only the 
short form of the 3A receptor was known in the CNS of humans. As a 
consequence researchers focused on the pharmacology and function of the 
homomeric 5-HT3AR. However, recent studies show that the 3B-subunit is also 
expressed in the human hippocampus [19], and transcribed in other areas of the 
brain, in amounts even higher than the 3A transcription, with a few different 
splice variants [20]. The solution to the problem of receptor heterogeneity and 
localization is quite important, as it is a prerequisite for adequately understanding 
5-HT3R involvement in the normal physiology of the CNS and its role in disease.
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While localization of individual subunits is amenable to immunohistochemical 
methods, determination of subunit composition of individual receptor is more 
difficult. This analysis will likely require new ligands that discriminate between 
different heteromeric and homomeric subtypes of the 5-HT3R in addition to single 
channel analysis. The development of new, subtype selective, pharmacological 
agents for the 5-HT3R family is critical to determining its distribution and role in 
disease.
1.7 The 5-HT3R primary binding site.
Site-directed mutagenesis studies on the murine (mouse) 5-HT3aR have 
identified a number of amino acid residues are important to binding agonists and 
competitive antagonists to the 5-HT3R [21]. Site directed mutagenesis studies 
have focused on regions of the 5-HT3R amino terminal homologous to the 
nAChR binding loops A-F (recall figure 1.2 above). Key amino acids have been 
identified in loop B [22], loop C [23] and loop E [24] of the short splice variant of 
the murine type A 5HT3R. Figure 1.5 shows the positions of these loops and 
some of the important residues, according to one model, which is based on the 
AChBP discussed in the next section and throughout this work.
Figure 1.5: Structure of the binding site of the 5-HT3R. Top and bottom left are views from the 
side of the receptor. The ligand serotonin (5-HT) is inserted on the bottom figures. Top and 
bottom right are views of the binding site rotated into the plane of the page; that is, viewed from 
the membrane side. Solid arrows indicate positions of residues as labelled, dashed arrows 
indicate the position of loops; in the bottom figures, dotted lines indicate the position of serotonin. 
Atoms are coloured as follows: Oxygen red, nitrogen dark blue, carbon black, hydrogen light blue. 
Figure was created using Protein Data Bank file 1I9B (AChBP [3]) and DeepView Swiss Pdb 
Viewer version 3.7.
In the loop B region, binding of the 5-HT3R antagonist granisetron appears 
to involve W183 (conserved in most cys-loop receptors). Mutation of W183 to Y, 
F or A (standard one-letter amino acid abbreviations [1] are used throughout this 
thesis) severely alters binding of all competitive ligands including serotonin.
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Binding of granisetron is also altered by mutation of H185, and D189 [22], The 
critical importance of W183 in all LGIC receptors and its apparent rigidity in the 
receptor structure has led to the suggestion that the B loop forms the center or 
foundation of the LGIC binding site. The strongly positive nitrogens of ligands 
such as serotonin are thought to from cation-pi interactions with the central 
tryptophan residue. This interaction alone would likely lend at least 8Kcal/mole 
of binding energy to the binding of serotonergic ligands.
Residues E225 and F226 in loop C of the murine 5-HT3AR appear to 
interact with the endogenous agonist serotonin but are less important to binding 
of granisetron. The conserved tyrosine residue Y234 in loop C was determined 
to be important for both granisetron and serotonin binding. Other putatively 
important amino acids in loop C included I228, D229, and S233, although these 
residues are not fully conserved between mouse and human 5-HT3aR’s (in the 
human they are M, E, and Y respectively). It is generally hypothesized that the 
Loop C region in LGIC’s may form a flexible loop that closes over the binding site 
when the agonist binds; thus trapping the ligand in the site. New interactions of 
agonists with loop C amino acids would promote stability of this new 
conformation thus providing energy for channel opening and desensitization.
This movement of loop C is consistent with increased affinity of agonists after 
channel opening. Antagonists are thought to be too large to allow this 
conformational change and do not appear to interact extensively with loop C 
amino acids.
In loop E, two tyrosines (Y143 and Y153, also sometimes called Y142 and 
Y152, respectively) were found to be important to binding of several agonists 
including serotonin and /77-chlorophenylbiguanide (/77CPBG) - a partial agonist. 
These residues did not substantially alter binding of granisetron but did affect 
binding of the newly discovered antagonist lerisetron. Lerisetron represents a 
new structural class of 5-HT3R antagonists and would thus likely interact slightly 
different with the 5-HT3R binding site. While it is unclear exactly what role the E
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loop plays in the 5-HT3R, it seems likely that it becomes more important to 
binding of agonists as the channel changes conformation to the open and 
desensitized states. This conformational change may involve a movement of the 
E-loop on the -  face of the binding site towards the + face. Similar to the C-loop 
this would lead to increased binding energy for agonists and provide energy for 
channel opening.
Other residues known to be important are the conserved W90 in the D- 
loop, and E129 in the A-loop [2], A more complete analysis of this topic is given 
in chapter 4.
1.8 Acetylcholine-binding protein (AChBP).
The AChBP (figure 1.6) was originally discovered in the great pond snail, 
Lymnaea stagna/is. Two additional homologues of this protein have also been 
identified in the sea hare Ap/ysia californica[25\ and freshwater snail Bu/inus 
truncatus [26]. In these gastropod molluscs this protein is thought to be secreted 
by glia and its presumed role is to regulate synaptic function through binding and 
sequestering of acetylcholine; but it is possible that it could have other functions 
as well, such as defending the organism against toxins. Sequence analysis 
suggests that this protein may have evolved as a result of a truncation of the 
nAChR in ancestral snails.
Figure 1.6: AChBP pentamer. A: bottom view. B: side view. From Protein Data Bank (PDB) file 
119B, [3], visualized using DeepView Swiss Pdb Viewer version 3.7.
The acetylcholine-binding protein (AChBP) [3, 27] has been used extensively 
in developing homology-based computer models of the N-terminal binding 
domains of cys-loop ligand gated ion channels (LGIC’s) [22, 23, 28-33]. The 
AChBP is thought to be structurally homologous to the amino terminal region of 
LGIC receptors based on the reasonably high sequence identity between these 
proteins (15-30%). Since it is a soluble protein, the AChBP has been crystallized 
and its structure determined to a resolution of 1.8A. The AChBP displays a 
pentameric quaternary structure very similar to the N-terminal domain of the 
nAChR determined from electron diffractions studies [5, 27]. In addition, amino 
acids within the binding site loops identified by affinity labelling and site directed 
mutagenesis on the nAChR correspond to amino acids located in the AChBP 
binding site. The combination of sequence homology, similarities in overall 
structure and location of loop regions suggests that the AChBP can be used to 
develop reasonably good models of LGIC binding sites.
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1.9 Introduction and significance of current work.
The similarity of the AChBP to LGIC binding domains raises the possibility 
that the AChBP could be used to mimic LGIC receptors. The AChBP is easily 
expressed and purified and can be produced in reasonably large amounts. The 
soluble nature of the protein and its ease of handling make it ideal for attachment 
to biosensor surfaces.
While the AChBP itself would be a useful biosensor, it would also be 
desirable to “tune” its selectivity so that it could be used to detect multiple classes 
of ligands. The presumed structural similarity between the AChBP and members 
of the LGIC superfamily may make it possible to alter the binding site interactions 
via site-directed mutagenesis and change the selectivity of the AChBP to favour 
5-HT3R ligands over nicotinic ligands. This approach will require detailed 
understanding of the interaction of ligands with both the target receptor (such as 
the 5-HT3R) and the AChBP. Models of interaction for different LGIC receptors 
and the comparative pharmacology of receptors ligands are available although 
more refinement may be necessary. Numerous mutagenic studies can provide 
the necessary information to begin mutating the AChBP. Pharmacological data 
of the AChBP itself is more limited.
1.9.1 AChBP pharmacology.
While the AChBP appears to be a good model for LGIC receptors and 
homology models based on this protein are available for nicotinic, GABA, Glycine 
and serotonin receptors, very little is known about the pharmacological selectivity 
of the AChBP. For example, while several labs have constructed homology 
models of the 5-HT3R and used these models to model the interaction of 
granisetron, lerisetron, o^tubocurare, serotonin and /77-chlorophenylbiguanide 
with this receptor, no comparative pharmacology has been done to determine the 
interaction of these compounds with the AChBP itself. Without pharmacological
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data for LGIC ligand interactions with the AChBP, any analysis of the quality of 
the docked homology model is flawed. To make matters worse, it generally 
appears to be assumed that AChBP pharmacology will mimic the nAChR and is 
unlikely to bind 5-HT3R ligands with any great affinity. This is an invalid 
assumption that may lead to incorrect binding models for 5-HT3Rs. Better 
pharmacology data for the AChBP would help distinguish between competing 
models of ligand/receptor interaction and improved homology models of these 
receptors. Better models of LGIC along with a comprehensive pharmacology of 
the AChBP can be used as a basis for protein engineering of the AChBP as a 
broad use sensor molecule.
1.10 Study Hypotheses and Objectives:
The overarching goal of this project is to use the AChBP as a lead molecule for 
the development of high throughput biosensor devices. This goal rests on two 
fundamental hypotheses:
1. The AChBP can be attached to biosensor surfaces and trigger a response 
that can selectively detect the presence and affinity of nicotinic ligands.
Objective 1.1: Develop an expression and purification scheme for the
AChBP that permits rapid purification of sufficient 
quantities of protein.
Objective 1.2: Determine the storage qualities of the AChBP in solution 
and identify ways of stably storing the protein over a long 
time period (months).
Objective 1.3: Determine the functionality of the receptor on three 
biosensor platforms -  Surface Plasmon Resonance, 
Scintillation Proximity Assay and Microcantilevers.
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Objective 1.4: Determine the sensitivity and stability of the AChBP on 
each of the platforms tested in Objective 1.3.
2. The A ChBP can be engineered to selectively recognize different classes of 
LGIC by mutating key binding site amino acids in the AChBP to 
corresponding amino acids of the target LGIC receptor.
Objective 2.1: Conduct pharmacological studies of the AChBP to
determine the affinity of a broad range of LGIC ligands with 
the AChBP in its native form
Objective 2.2: Construct point mutations based on predictions from 
homology modelling and ligand studies of the binding 
domain of the serotonin type 3 receptor, which will increase 
affinity of serotonergic ligand and decrease affinity of 
nicotinic ligands (i.e. Alter the selectivity of the protein to 
one similar to the 5-HT3R.).
Objective 2.3: Using information obtained as a result of Objective 2.2, 
create additional Binding proteins aimed at mimicking 
selectivity of 5-HT3R subtypes.
(Long term objective -  not part of the current thesis).
Materials and methods utilized to accomplish these objectives are found in 
Chapter 2 of this thesis. Objectives 1.1-1.4 are addressed in Chapter 3 {AChBP 
as a molecular biosensor) and Objectives 2.1 and 2.2 are addressed in Chapter 
4 (Binding of serotonergic ligands to the AChBP). Only limited data is presented 
(in supplementary material) for Objective 2.2. Objective 2.3 is a long term 
objective of the overall study and the project is not yet ready to address this 
point. Chapter 5 summarizes all efforts to date and indicates future directions 
and goals of the project.
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Chapter 2: Materials and Methods.
2.1 Construction of AChBP-containing plasmid DNA.
AChBP cDNA identical in sequence to the molluscan snail Lymnaea 
stagna/is was commercially synthesized and inserted into a p3xFLAG-CMV-9 
vector containing a C-terminal 6x Histidine region and an N-terminal p3-Flag 
epitope tag. The vector also contains a G418-resistant gene for selection of 
stable transfectants in mammalian cell lines. Synthesis and cloning was 
performed by GENEART (Regensburg, Germany).
2.2 Amplification of AChBP Plasmid DNA.
XL1-blue supercompetent E. co/icells were transformed with the 
AChBP/p3XFIag-CMV-9 DNA using a standard protocol and reagents provided 
by Stratagene. (Stratagene, Cedar Creek, TX, USA, catalogue #200236). Minor 
modifications to this protocol were made: The procedure was scaled down by 
50%, and beta-mercaptoethanol was omitted. DNA was purified by Qiagen Maxi- 
prep (Qiagen, Maryland, USA), using Qiagen’s protocol. DNA was verified by 
restriction digest followed by agarose electrophoresis.
2.3 Stable transfection of AChBP in Human Embryonic Kidney.
DNA prepared by Qiagen Maxi-prep was used to develop stably 
transfected HEK293 cell lines (Human embryonic kidney cells, ATCC) that 
actively secrete an intact AChBP. Development of stably transfected cell lines 
results in consistent production of AChBP protein, high yields (1 mg per litre 
media) and rapid purification using the 6X His nickel binding region or AntiFlag 
antibody.
2.3.1 Growth conditions for HEK 293 cells.
HEK293 cells were grown in DMEM media (catalogue #30-2003, ATCC, 
Manassas, VA, USA) supplemented with 10% Fetal Bovine Serum, (Gibco/
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Invitrogen catalogue #16000-044), 2% Penicillin/streptomycin (Invitrogen 
catalogue #15070-063, prepared with 5000units/ml penicillin, 5000 mg/ml 
streptomycin sulphate in 0.85% saline), and G418 antibiotic (Sigma cat. no. 
G8168) at varying concentrations. Cells were incubated at 37 °C in a humidified 
atmosphere of 5% CO2 in a Napco C02 5400 Growth chamber. Falcon cell 
culture flasks (250 ml) were used for growth and maintenance, and 100mm 
dishes were used in plating cells for transfection. Cells were split into new flasks 
when 95-100% confluent (usually weekly). Following removal of culture medium, 
cells were washed once with 10 ml of warm Dulbecco’s phosphate buffered 
saline (DPBS, placed in 37 °C water bath -20 minutes before use), then 
incubated 60 seconds with 5 ml of warm trypsin (0.25% trypsin EDTA, 
Gibco/lnvitrogen, Carlsbad, CA) and re-suspending in 10 ml new DMEM. Re­
suspension was performed by repeated up and down pipetting using a transfer 
pipette. Typically, 0.5 ml of the cell suspension was diluted with 24.5 ml of warm 
growth media and the mixture transferred to a new flask. Cell culture flasks were 
re-used a maximum of three times, and handling of cells was performed under 
semi-sterile conditions: Bottles, gloves, and other equipment were wiped with 
70% aqueous ethanol before being used under a laminar flow hood pre-exposed 
to UV light for one hour.
2.3.2 Dose response for HEK293 cells incubated with G418.
Prior to transfection, a kill curve (dose response curve) for HEK293 by 
antibiotic G418 was established (BD Biosciences protocol #PT3132-1, version 
#PR43789). Briefly, untransfected HEK293 cells were plated at a cell density of 
106 cells/cm2, and incubated in normal media and growth conditions (described 
above) with G418 added over a range of concentrations. The optimal 
concentration is considered to be that which results in 90% cell death in one 
week (ED90) and 100% death within two weeks. Cells are considered dead when 
they become round and fail to adhere to the dish. Based on these criterions, it
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was determined that the optimal G418 concentration in which to grow the cells 
was between 0.2 and 0.4 mg/ml.
2.3.3 Stable Transfection of HEK293 cells with AChBP plasmid.
Stable transfections were performed using the Qiagen SuperFect reagent 
kit and protocol (Qiagen, catalogue #301307). Cells were maintained in G418- 
free medium for 48 hours directly following transfections. A sample of the 
medium was taken at this point and assayed for AChBP expression using 
radiolabelled 3H-epibatidine. Medium was then replaced with fresh DMEM 
containing either 0.4 mg/ml or 0.3 mg/ml G418. The 0.4 mg G418/ml line was 
transfected using the standard 30 jul: 5 |jg superfect:DNA ratio suggested by the 
Qiagen protocol. Cells recovered very slowly and over one month of incubation 
was required before sufficient cells were obtained to permit efficient harvesting of 
the expressed AChBP. Cells grew well after this point. The 0.3 mg G418/ml line 
was transfected using an optimized 50 (j.l: 5 |jg superfect:DNA ratio. This cell line 
showed faster growth and produced a usable cell line in about 2 weeks.
2.4 Growth and harvest of AChBP from transfected cell media.
The 0.4 mg/ml G418 cell line was chosen for expression of AChBP. Stably 
transfected cells were maintained in 250 ml, 75 cm2 cell flasks until they reached 
95% confluence. They were then transferred to larger dishes suitable for large 
scale protein production. Cells were washed once with PBS, incubated 60 
seconds with 5 ml trypsin, and resuspended in 10 ml media by pipetting 10-20 
times against the bottom of the flask. 2.5-3.0 ml of resuspended cells were 
transferred to large cell culture dishes (VWR catalogue #BD351040, 600 cm2) 
containing 110-130 ml of 0.4 mg/ml G418-containing media (described above). 
Cells were incubated as described above, and cell culture media was collected 
every 2-4 days, usually at days 3, 5, and 7, corresponding to confluence levels of 
about 30%, 80% and 95%, respectively.
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2.5 Purification of AChBP.
AChBP was purified from the cell culture medium using Sigma Nickel-EDTA 
His Select Columns. Collected medium was prepared for purification by addition 
of salts to concentrations of 50 mM Na2HP04,0.3 M NaCI and 10 mM imidazole. 
Sodium hydroxide (1 M, about 25 ml per 500 ml media) was used to adjust the 
pH to 7.5, and the media was filtered through 0.4 or 0.2 [jm cellulose acetate 
filters. This protocol is a modification of the Sigma His-Select column product 
H8286 protocol. The addition of NaCI served to increase the ionic strength of the 
solution and imidazole is used to decrease non-specific binding to the affinity 
column. Adjusted culture medium was loaded onto equilibrated Nickel-EDTA 
His-Select columns (Sigma #H8286) at a flow rate of 1 ml/min using a peristaltic 
pump. The medium was placed on ice for the duration of this process, which 
lasted 2-5 hours. This process was preceded and followed by equilibrating the 
column with 5-10 ml/column of a media-free equilibration buffer, also 50 mM 
Na2HP0 4 ,0.3 M NaCI, 10 mM imidazole, and adjusted with sodium hydroxide to 
pH 7.5. Elution was accomplished with 5-7 ml/column of a PBS buffer made 
similarly to the equilibration buffer above, except sodium hydroxide is replaced 
with 250 mM imidazole. Elution was performed in 1.5 ml fractions, with most of 
the AChBP appearing in the second fraction.
AChBP was found to elute with significant amounts of imidazole, which 
required removal since it interfered with protein quantification. To remove 
imidazole, we first utilized membrane dialysis using a 12-14 kilodalton (kD) 
molecular weight-cutoff dialysis tubing overnight in 1000-fold excess of 
phosphate buffered saline (PBS, used for scintillation proximity assay (SPA) 
described below). While this method was effective, it was more efficient to use 
30 kD MW-cutoff MicroSep centrifugal filters (Pall life Sciences, Ann Arbor, Ml). 
Use of MicroSep filters produced equally pure AChBP in about 2 hours. Eluant 
was applied to filters then concentrated by centrifuging at 6000 g for 40 minutes.
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Two washes of 3-4 ml PBS/wash were performed to remove excess imidazole 
and the protein was removed from the filter by addition of 1 ml of PBS.
2.6 Analysis of AChBP using Lowry Assay and Electrophoresis.
Expression and purification of AChBP from the 0.4 mg/ml G418 cell line 
yielded about 1-4 mg protein per litre of medium, as determined by Lowry assay, 
(Sigma’s Micro Lowry Kit, Peterson’s Modification, Catalogue #TP0300).
Gel electrophoresis was performed under non-denaturing (TG buffer, 
BioRad native sample buffer), and denaturing (TGS buffer, Laemli sample buffer) 
conditions, using standard BioRad procedures, on a BIO-RAD Mini-Protean 3 
Cell. BioRad kaleidoscope standard was used, and constant 200 V was applied 
for 20-35 minutes until the dye front was close to the end of the gel. Precast 
7.5% and 12% tris-HCI BioRad gels were used in all experiments. AChBP was 
identified as the 30 kD band under denatured conditions and about 150 kD under 
non-denaturing conditions. No bands of similar molecular weight were observed 
in a control untransfected-HEK293 media sample. Since the non-denatured 
protein was approximately 5 times the size of the denatured protein it was 
concluded that the protein expressed as a pentamer as expected. No bands 
were observed corresponding to any other stoichiometry including dimers or 
trimers. The AChBP in samples was visually estimated to be up to approximately 
90% pure.
Purity of the AChBP had no observed effect on later scintillation proximity 
(SPA) assay. Since the SPA beads use nickel affinity to binding the AChBP, 
preparation of the beads essentially constitutes a second purification step. In 
addition, since any contaminating proteins are unlikely to bind LGIC ligands, a 
very low non-specific binding was observed. Media purified from untransfected 
cells gave little or no SPA response (data not shown) even at high levels of 
radioligand. The “non-specific” binding observed with high levels of 3H-
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granisetron and epibatidine on AChBP-treated SPA beads is thus likely due to 
binding at secondary, low affinity sites on the AChBP protein itself.
2.7 Vacuum drying of AChBP.
In order to facilitate storage and increase stability of the AChBP, we 
attempted to dry the purified AChBP then reconstitute it. We determined that the 
AChBP was resistant to denaturation under these conditions and could be easily 
dried and reconstituted. Stability was greatly increased in dried samples. Prior 
to drying, the AChBP was concentrated to 700 pg/ml in PBS, aliquotted into 200 
pl_ portions, and placed in 0.5 ml micro-centrifuge tubes, un-capped. Tubes were 
spun under vacuum in a rotatory evaporator (DNA Speed Vac model DNA 110, 
Savant Instruments, Holbrook NY: “drying rate” on low, “concentrator” on) at 
ambient temperature for two or three hours until dry. Dried samples were then 
refrigerated for up to 12 months at 2-8 °C. No differences in protein composition 
or binding characteristics were observed using PAGE or SPA assays between 
samples taken before drying, immediately after drying, or after several months of 
storage. This topic is covered in more detail in chapter three.
2.8 Scintillation Proximity Assay (SPA).
Scintillation Proximity Assay (SPA) provides a rapid, high-throughput 
assay for evaluation of receptor ligands. This assay differs from a conventional 
ligand binding assay in that the protein is bound to a suspended bead matrix 
coated with copper. AChBP was bound to the beads using the 6X His tag. 
Scintillant is integrated into the bead matrix. Only radioligand bound at close 
proximity to the bead excites the scintillant. Using this system, no filtration is 
necessary for the separation of bound and unbound ligand since only bound 
ligand produces a signal. This enables both rapid analysis of binding data and 
the use of low affinity ligands.
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In our assays, PVT Copper His-tag SPA beads (GE/ Amersham 
#RPNQ0097) were diluted with phosphate-buffered saline to 0.1 or 0.5 mg beads 
per ml, and optimized amounts of Kis-tagged AChBP were added. Bovine Serum 
Albumin (BSA, Sigma; 2 mg/ml) was added to decrease non-specific binding. 
Mixtures were incubated at ~21°C (room temperature) for approximately one 
hour before ligands were added, and samples were counted a few hours to a day 
later on a 1450 Microbeta Plus liquid scintillation counter (Perkin-Elmer). Counts 
were taken over one minute at a time every five minutes for at least 25 minutes, 
and then averaged. Data reported results from the average and standard error of 
at least four experiments performed on different days.
2.8.1 SPA 3H-epibatidine and 3H-granisetron binding.
For 3H-epibatidine radioligand binding, 0.1 mg/ ml beads in phosphate 
buffered saline (PBS, see appendix 2), were incubated one hour with 2 mg/ ml 
BSA, and 0.0125 nM AChBP. Three ml of this suspension was added to 4-ml 
scintillation vials. Seven concentrations of 3H-epibatidine were added increasing 
by three-fold from 0.004 nM to 3.0 nM. These and one zero were capped and 
shaken for one minute, incubated for one hour at room temperature, and then 
counted. At Bmax, a typical response was 1000 counts per minute (CPM), with a 
percent error of about 5%. 3H-epibatidine radioligand was obtained from GE/ 
Amersham Biosciences and had an activity of 53.0 Ci/mmol.
3H-granisetron binding was performed similarly, except 0.5 mg/ml beads 
were used, and only 200 pi of beads/radioligand mix were required. 3H- 
granisetron concentrations were varied between about 1.0 nM and 240 nM. 
Nonspecific binding was determined in the presence of 1.0 M acetylcholine, and 
was subtracted. Incubation time was increased to at least two hours. 3H- 
granisetron was obtained from Perkin Elmer.
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2.8.2 SPA Competition assays.
3H-epibatidine (1.0 nM) was used as the radioligand in competitive binding 
assays. An AChBP concentration of 0.025 nM in 3 ml of PBS/BSA/Beads was 
used for all competition assays. At least 6 concentrations of competitor, flanking 
the Ki in 3-fold intervals, were used to acquire final data. Care was taken so that 
bound radioligand remained <10% of total ligand, assuming five binding sites for 
AChBP and data were corrected for loss of free ligand. The competing ligand 
was added before the radioligand, and incubated after shaking for at least two 
hours. However, variations on the incubation time had little effect on IC50 values. 
(Supplementary material is available for this section)
2.8.3 SPA Data Analysis.
Data was analyzed using Graph Pad Prism 4.0 software. The Kd values 
fo r3H-Epibatidine (using 0.0125 nM AChBP) and 3H-granisetron (using 2.6 nM 
AChBP) were calculated using the simple one-site binding model shown in 
equation 1:
Equation 1 Y = Bmax*X / Kd + X,
where X is radioligand concentration and Y is the response in CPM (proportional 
to bound ligand). For epibatidine, the non-specific binding signal (as determined 
independently by competition with excess competitor), was «10% , and was 
ignored. Non-specific interaction of granisetron with AChBP-bound beads was 
linear with ligand concentration, and was determined in parallel experiments and 
subtracted. The IC50 for the inhibition of epibatidine, and Hill-slopes (n) were 
determined for ligands using the sigmoidal dose-response equation and Graph 
pad Prism software:
Equation 2 Y = Bmax / (1 + io®°8<IC50>*l ‘ n))
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where X is the logarithm of the concentration of cold ligand, Y is the response in 
CPM, and n is the Hill slope. The Kj was calculated using the Cheng-Prusoff 
equation: Kj = IC50 * (Kd(epi)/[epi]). Data for individual experiments were 
normalized by dividing by the experiment’s calculated Bmax so that experiments 
with different Bmax values could be compared and/or combined.
2.9 Surface Plasmon Resonance (SPR).
Surface Plasmon Resonance (SPR) assays were carried out using a 
BiaCore 2000 plasmon resonance instrument (BIACORE AB, Uppsala, Sweden) 
and the BiaCore CM5 Sensor Chip and other appropriate chips. These chips 
were used to immobilize anti-Flag antibodies or the AChBP itself. AChBP 
purified from the Sigma His-Select columns or eluted from polyacrylamide gels 
was directly identified using the anti-FLAG chip, thus allowing identification of the 
AChBP protein.
SPR detection of ligands is limited to molecules of molecular weight 
greater than 180 Daltons. For larger molecular weight compounds such as d- 
tubocurarine (dTC), and a-bungarotoxin, both SPA and SPR assays were used 
and therefore serve to validate each other in evaluating the performance of the 
AChBP. Mutants of the AChBP are also undergoing such testing. Comparing Kd 
values obtained with SPA versus SPR for compounds such as physostigmine 
could also be used to determine if the binding site for that compound is the 
primary binding site or an allosteric site. The SPR assay is particularly useful for 
obtaining information on and off rates of interaction, as well as thermodynamic 
information for large compounds if needed. For AChBP-SPR applications, the 
AChBP is immobilized on a CM-5 surface using the EDC/NHS method (amine 
coupling). Data generated by SPR is analyzed using BIAevaluation software, 
version 3.0. Kinetic rate constants are globally determined by fitting the biosensor 
data using numerical integration and nonlinear least squares analysis. Several 
binding models are available and a mass-transfer rate constant can be included
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in the models to account for diffusion of molecules of analyte from the solution to 
the biosensor interface according to Fick's law, where appropriate [34],
2.10. Microcantilever (MC) Evaluation.
Microcantilevers (MC) have potential as sensitive, cost-effective 
biosensors for medical diagnostics and environmental testing. Microcantilever 
experiments were performed in Dr. Hai-feng Ji’s laboratory at Louisiana Tech 
University by Dr. Ji and his students. The AChBP was used as published (Gao 
et al, [35]) to evaluate an improved method of adsorption of a self-assembled 
monolayer (SAM) film to a commercially available silicon-chromium-gold 
microcantilever (Veeco Instruments). This improved method employed a 
trifluoroacetic acid wash protocol to improve AChBP immobilization and binding 
response. To assure the quality of the AChBP was not affected by shipping to 
Louisiana, the AChBP provided to Dr. Ji was vacuum-dried (see section 2.7) and 
equivalent samples evaluated in our laboratory using SPA and SPR assays. 
AChBP was bound to the microcantilever using a method similar to what we 
employed for SPR, and the bending response of the cantilever to applied 
acetylcholine (indicating a conformational change in the protein) was measured. 
The improved method was critical to the observation of a conformational change 
of AChBP on binding acetylcholine. This work is further addressed in Chapter 3.
28
Chapter 3: The AChBP as a Molecular Biosensor
As described in Chapter 1, the soluble nature of the AChBP protein, its 
ease of handling and the similarity of its binding site to LGIC receptors makes it 
an ideal lead molecule for developing a family of biosensor proteins. To evaluate 
the feasibility of this idea, we utilized the wild type cloned AChBP protein 
(chapter 2) as a biosensing molecule on three different biosensor surfaces: 
scintillation proximity assay (SPA), surface plasmon resonance (SPR) and 
microcantilevers (MC).
This chapter describes the development of an expression system for 
AChBP, its purification, characterization and attachment to sensor platforms.
The experiments in this section are designed to test Hypothesis 1 in section 1.10 
(Chapter 1) of this thesis and address Objectives 1.1-1.4. These data 
demonstrate the effective production of the AChBP protein using HEK293 cells, 
and its successful utilization as a biosensor. The SPA experiments demonstrate 
its potential for high-throughput screening and the SPR and microcantilever 
experiments demonstrate its usefulness on chip-based instrumentation. In 
addition, its use in “conformational change-” based sensing demonstrates an 
improved technology for microcantilever biosensors. [35]
3.1 Introduction.
The acetylcholine-binding protein (AChBP) has been used extensively as 
a template for computer based modelling of the N-terminal domain of Cys-loop 
ligand-gated ion channels (LGIC’s) [22, 23, 28-33]. In this chapter, its use as a 
biological sensor for detection of LGIC ligands is explored. As mentioned in 
chapter 1, the AChBP is known to bind ligands which also bind to nicotinic 
acetylcholine receptors (nAChR). While its broader specificity is unknown, 
structural similarities to other LGIC receptors suggest AChBP analogs could be
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engineered to match the selectivity of other receptors including the GABA,
Glycine and Serotonin type 3 receptors.
To be used as effective biosensor molecules, the AChBP proteins must be 
easily produced, purified and stored. In addition, the proteins must have a 
reasonably long shelf life (stability) and be able to be transported easily. Of 
course, they must also function correctly and provide a reasonable signal to 
noise ratio when attached to biosensor surfaces and exposed to ligands. This 
study aims to evaluate our cloned wild type AChBP protein from this perspective.
If the AChBP can be shown to meet the requirements for a biosensor 
molecule outlined above, it could be useful in a number of biosensor applications. 
Systems amenable to the use of AChBP type proteins include Scintillation 
Proximity Assay (SPA), as well as chip-based instruments such as Surface 
Plasmon Resonance (SPR), and Microcantilevers (MC). These systems differ in 
their potential applications, sensitivity, detection methods and cost.
3.1.1 Scintillation Proximity assay.
Scintillation proximity assay (SPA) is a bead-based assay that utilizes an 
affinity medium (SPA beads) coated with a scintillant. The receptor protein of 
interest is typically bound to the bead surface using either copper chelation or 
antibody binding. The protein/bead is then exposed to a radioligand and, after an 
appropriate incubation time, is placed in a scintillation counter to determine the 
amount of ligand bound in close proximity to the bead surface (figure 3.1). SPA 
represents a technological advance over conventional radioligand binding assays 
which have become the standard for obtaining LGIC pharmacological data (for 
examples, see [23, 33]). Conventional LGIC binding assays are often conducted 
similar to the SPA assay but all require filtration of the protein to separate bound 
and unbound ligand prior to scintillation counting. The incorporation of scintillant 
into the bead eliminates the filtration step since only radioligand bound in close 
proximity to the bead surface is capable of exciting the scintillant. Elimination of
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the filtration step makes it easier to automate the technique and thus permits 
high throughput assays to be developed. Although SPA beads can also be used 
with ordinary cell-membrane homogenates, the SPA process is particularly well 
suited to a soluble protein such as the AChBP or engineered AChBP analogs.
A ChBP
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Figure 3.1. SPA Schematic. In the diagram at left, the radioligand is in close proximity to the 
bead, and the emitted (3-particle causes the scintillant coating of the bead to emit a photon, which 
is detected by the counter. At right, unbound ligand is not close to the bead, and thus does not 
excite the scintillant. Diagram is not to scale: beads are 2-8 |jm in diameter, the average path 
length for tritium (3H) decay is 1.5 |jm, AChBP pentamer 8 nm across, and 3H-epibatidine 
radioligand is ~1nm long. Picture adapted from SPA Handbook (GE/Amersham Biosciences).
The SPA process is quite simple: First, the receptor protein (such as the 
AChBP) is mixed with the SPA beads and an appropriate buffer. Copper on the 
SPA bead binds to the 6X His tag on the C-terminal of the AChBP, immobilizing 
the protein on the bead surface. Varying concentrations of ligand are added and 
the fraction of ligand bound to the protein/beads is determined by scintillation 
counting. An equilibrium binding constant (Kd) for the radioligand is calculated 
from a plot of radioligand concentration vs. fraction bound similar to conventional 
binding assays. Inhibition assays can also be used to determine the affinities (Ki 
values) of compounds not available in radiolabelled form. One major advantage 
over conventional assays which require a filtration step is the ability of using SPA 
assays with lower affinity ligands. Since filtration is not required, there is no 
danger of washing away a low affinity ligand during washing of the filters.
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3.1.2 Surface plasmon resonance.
Surface plasmon resonance biosensing is a relatively new technology 
developed by Biacore Inc. (www.biacore.com). This chip-based technology 
depends, as the name implies, on the phenomenon of plasmon resonance. 
Plasmon resonance was first observed by Turbadar in 1959 [36], but was not 
used in biosensing until much later. Plasmon resonance refers to the excitation 
of surface plasmons by light. Surface plasmons are electromagnetic waves that 
propagate along a metal surface in close proximity to the surface. These waves 
are dependant on the surface interface and are altered by surface 
characteristics. Molecules binding to the surface interact with the wave, altering 
its properties. In a typical conformation a gold coated glass chip is sandwiched 
between a microfluidics cell and a prism (figure 3.2) Incident light is directed 
through the prism at an angle that produces total internal reflection. The incident 
light interacts with surface plasmons generated at the gold surface (and is 
influenced by the surface characteristics). This interaction alters the angle of 
reflection of the incident light and this change is monitored by the SPR 
instrument. Thus, the output of the SPR instrument is essentially a 
measurement of changes in this angle that correspond to ligand binding to the 
gold surface. These changes are directly related to the molecular weight 
changes at the gold/ buffer interface. Hence, SPR measures changes in 
molecular weight over time.
The gold surface of the plasmon resonance chip is typically coated with 
coupling reagents that allow proteins or small molecules to be attached to the 
chip surface. Since this technique measure changes in molecular weight, it 
works best when the lower molecular weight binding partner can be attached to 
the chip and the higher molecular weight molecule is placed in the flow cell.
The detection limit for ligands binding to the chip for the Biacore instrument is 
typically considered to be about 180 atomic mass units (amu).
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Figure 3.2. Schematic of the Biacore SPR system. The properties of the gold surface (yellow) 
change as molecules bind to the chip surface. These properties depend on mass of the molecule 
and the properties of the solution. Alterations of the gold/ solution interface alter the surface 
plasmon waves resulting in change in the angle of reflection. The Biacore 2000 instrument 
monitors this angle and produces and output measured in resonance units (RU). Picture from 
Biacore TN1 handbook[34].
3.1.3 Microcantilevers.
A microcantilever sensor is a metallic device that bends when molecules 
bind to one side. This bending can be detected using optical or piezoelectric 
methods (Figure 3.3) [37]. Microcantilevers have several advantages over 
conventional sensors including small size, great sensitivity and the ability to 
detect molecules that are not labelled. Microcantilevers are cost-effective and 
highly sensitive sensor platforms with potential applications in medical 
diagnostics, environmental monitoring, and high throughput analysis [38-40].
Figure 3.3: Schematic of the microcantilever mechanism. The biosensor protein (left) is bound to 
one side of the microcantilever. Ligand, right, binds to the protein; steric effects, charge effects 
and/or a conformational change causes the surface to expand (as shown) or contract. This 
expansion or contraction of only one side causes bending which is detected optically or 
piezoelectrically (see text).
Adsorption or intercalation of the analyte on one side of the 
microcantilever can change the chemical characteristics of the surface or alter 
the film volume on the surface. Microcantilevers can bend down [38] or up [37] 
upon binding of specific species in the environment depending on the effect 
binding produces. From a molecular point of view, the bending results from 
intermolecular interactions such as electrostatic attraction [37], repulsion [41], 
steric effects [38], or a combination of these, which alter the surface stresses on 
the cantilever. By monitoring changes in bending response of a cantilever, 
surface stress changes induced by adsorption or molecular recognition can be 
precisely and accurately recorded. Bending is easily detected optically using a 
system such as that shown in Figure 3.4. For piezoelectric detection, the 
microcantilever is mounted on a piezoelectric device and changes in the 
electrical properties of the piezoelectric stack that result from bending are 
measured. The advantages of piezoelectric detection are more sensitivity, 
increased stability and the ability to put a large number of microcantilevers 
directly into a microchip device.
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Figure 3.4. MC Schematic with optical detection. Analyte is introduced into the flow cell (liquid 
cell) via a switch. The bending of the microcantilever (MC) is detected as a change in position of 
the reflected light hitting the detector. Figure is reproduced from Gao et al. [35].
The microcantilever assays described in this thesis were done in Dr. Hai- 
feng Ji’s laboratory. This work represents the first use of AChBP as a 
microcantilever biosensor and demonstrates an improved method of 
microcantilever coating, as described in section 3.2.6.
3.2 Materials and Methods.
3.2.1 Engineering of the AChBP biosensor protein.
AChBP DNA from Lymnaea stagna/is was synthesized commercially and 
inserted into the p3xFLAG-CMV-9 vector with a C-terminal 6x “His tag” and an N- 
terminal p3-Flag tag. The p3xFLAG-CMV-9 vector contains a gene that confers 
resistant to the antibiotic G418 for use in selecting transfected mammalian cells. 
This DNA was used to stably transfect HEK293 cells, which actively secrete 
AChBP into the surrounding media as described in chapter 2. The 6X C-terminal 
His tag allowed the protein to bind to metals such as copper and nickel, and was 
included as a rapid means of purifying the protein (using Nickel-EDTA columns, 
Sigma). The Flag tag was originally included to provide a secondary option for 
purification (using an anti-Flag affinity column) but was not used since the Nickel
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affinity columns provided sufficient purity. The Flag tag was used in some of the 
SPR experiments as a way of identifying and immobilizing AChBP on the sensor 
surface, however; the preferred choice for SPR immobilization was amine linking 
as described below (section 3.2.5). An N-terminal flag, C-terminal 6x-His 
AChBP similar to this one was previously expressed by Hansen et al [42]. The 
His-tag and Flag tag were both shown to be accessible to purification (i.e. they 
were not buried) and the tags do not seem interfere with normal binding [3].
3.2.2 Expression/purification of AChBP.
AChBP was expressed and purified as described in Chapter 2. Briefly, 
His-tagged AChBP was expressed in HEK293 cells, which actively secreted the 
AChBP into the medium. AChBP-secreting cells took about 2-3 days to produce 
approximately 1 mg protein per litre of culture medium. While this is relatively 
modest yield, it should be noted that this is a large amount of protein for use in 
assays such as SPA and SPR. Medium was collected, buffered (pH 7, high ionic 
strength) and processed as described in section 2.5. The AChBP was extracted 
from this media using nickel-EDTA purification columns, and eluted with 250 mM 
imidazole. The protein was then pooled and concentrated in PBS to a 
concentration of 700 jjg/ml using 30 kD MW-cutoff MicroSep centrifugal filters 
(see section 2.5). The AChBP was then dried and reconstituted prior to use. 
AChBP shipped for microcantilever analysis in Dr. Ji’s laboratory was dried prior 
to shipping and reconstituted in Dr. Ji’s laboratory with distilled H20.
3.2.3 Drying of AChBP.
We initially attempted to preserve AChBP by freezing AChBP-containing 
medium. This process significantly interfered with purification. Freezing the 
medium produced a precipitate that decreased the yield of AChBP to 
undetectable levels. As an alternative storage and transport method, we 
attempted to dry the protein.
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AChBP was dried at room temperature under a vacuum. AChBP was 
concentrated to 700 (jg/ml (5200 nM) in PBS, aliquotted into 200 |jl_ portions, and 
placed in 0.5 ml micro-centrifuge tubes, un-capped. Tubes were spun under 
vacuum in a rotary evaporator (DNA Speed Vac model DNA 110, Savant 
Instruments, Holbrook NY: “drying rate” on low, “concentrator” on), spinning 
under partial vacuum at ambient temperature for two or three hours until dry. 
Samples were then refrigerated for up to 12 months at 2-8 °C. The reconstituted 
protein showed properties (binding and structural) identical to that of the freshly 
purified proteins (see section 3.3.1).
3.2.4 Scintillation Proximity Assay.
The SPA assay is performed similar to conventional radioligand binding 
assays as described in Chapter 2. Scintillation vials were read using a Perkin- 
Elmer Microbeta Plus Scintillation Counter. For SPA assays, SPA beads were 
mixed in a scintillation vial with medium containing the protein of interest (in this 
case AChBP). The AChBP binds to the copper chelated on the bead surface via 
the 6X His tag. Radioligand at the appropriate concentration was added, and (if 
desired) a competing ligand. The mixture was allowed to equilibrate (1-2 hours) 
before counting. Since only radioligand bound to protein on the bead surface 
can excite the scintillant, no separation of bound and unbound ligand by filtration 
is necessary. One of SPA’s advantages as a bioassay is that it is at once both a 
purification step and an analysis.
As described above, imidazole was typically removed from the eluant 
during purification since it interferes with the Lowry assay used to determine the 
total protein concentration. However, removal of the imidazole was not 
necessary in order to observe high-affinity binding of 3H-epibatidine using SPA 
assay. We observed that imidazole appears to improve the stability of AChBP in 
solution when stored at 2-8 °C (data not shown), probably due to stabilization of 
the single pentamer structure and preventing “clumping” of individual proteins.
37
Hansen et al [25] observed pentamer-dimerization of AChBP on storage. In 
addition, we discovered that the AChBP is not stable for long periods when 
diluted to -15 nM in the PBS used for the SPA assays. Hence for SPA assays, 
the AChBP was diluted with PBS immediately before addition of the SPA beads.
3.2.4.1 Binding of 3H-epibatidine.
For evaluation of 3H-epibatidine binding, the protein was diluted to 15-50 
nM in PBS, then further diluted with an SPA bead suspension (0.1 mg beads/ml 
beads and 2 mg BSA/ml in PBS (see appendix 2)) to a final concentration of 
0.0125 nM AChBP. After a one hour incubation period, three ml of this 
suspension were added to 4-ml scintillation vials. Seven concentrations of 3H- 
epibatidine were added increasing by three-fold from 0.004 nM to 3.0 nM (final 
concentrations). The 3H-epibatidine samples and a control sample (no 3H- 
epibatidine) were capped and shaken for one minute then incubated for one hour 
at room temperature prior to counting using a scintillation counter. At saturating 
concentrations of 3H-epibatidine, the calculated Bmaxwas typically about 1000 
counts per minute (CPM). Nonspecific binding was considered to be the binding 
observed in the presence of a saturating concentration of a second, competitive 
ligand. In these experiments, nonspecific binding was comparable in magnitude 
to the instrumental background noise (10-50 cpm); thus it was ignored in the 3H- 
epibatidine Kd calculations. The high sensitivity for specific binding and low non­
specific binding was found to be an advantage of the SPA assay system.
3.2.4.2 Binding of 3H-granisetron.
3H-granisetron binding was performed similarly to 3H-epibatidine binding 
described above, except that the bead suspension contained 0.5 mg beads per 
ml, 2.6 nM AChBP final concentration, and only 200 pi of bead suspension per 
sample were required. 3H-granisetron concentrations were varied between 1.0 
nM and 240 nM. Nonspecific binding was determined in the presence of 1.0 M
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acetylcholine, and was subtracted from total binding to give specific binding. 
Nonspecific binding was about 5% or less of total binding. This increase in non­
specific binding compared to that obtained using 3H-epibatidine is likely due to 
the lower affinity of 3H-granisetron and thus the use of much higher 
concentrations than were employed in the 3H-epibatidine experiments.
Incubation time for granisetron was at least two hours.
3.2.4.3 SPA Competition assays.
3H-epibatidine (1.0 nM) was used as the radioligand in competitive binding 
assays. Competition experiments used 3 ml of 0.025 nM AChBP in bead/ PBS 
suspension. At least 6 concentrations of competitor, flanking the Kj in 3-fold 
intervals, were used to acquire final data. Care was taken so that bound 
radioligand remained <10% of total ligand and free ligand concentration was 
calculated as Total ligand -  Bound ligand. The competing ligand was typically 
added before the radioligand, and the combined mixture was incubated after 
shaking for at least two hours. Variations on the incubation time had little effect 
on IC50 values.
3.2.4.4 SPA data analysis.
Data was analyzed using Graph Pad Prism 4.0 software. The Kd’s for 3H- 
epibatidine (0.0125 nM AChBP) and 3H-granisetron (2.6 nM AChBP) were 
calculated using the simple one-site binding model:
(Equation 3.1) Y/Bmax =X / Kd + X
where X is radioligand concentration and Y is the count per minute response 
(proportional to bound ligand). For epibatidine, the non-specific binding signal 
(radioligand interacting directly with beads or non-specifically with AChBP), was 
<10%, even at twenty times the Kd, and was ignored. Non-specific interaction of 
granisetron was linear with ligand concentration, and was determined in parallel 
experiments and subtracted. The Ki (from IC50) for the inhibition of epibatidine,
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and Hill-slopes were determined for ligands using the sigmoidal dose-response 
equation and Graph pad Prism software:
(Equation 3.2) Y/Bmax = 1 / (1 + 10([log(IC50)-X] *Hi"slope))
where X is the logarithm of the concentration of cold ligand and Y is the response
in CPM. The Kj was calculated using the Cheng-Prusoff equation: Kj = IC50 *
(Kd(epi/[epi]).
3.2.5 Surface Plasmon Resonance (SPR).
Plasmon resonance assays were performed using the BiaCore 2000 
plasmon resonance instrument and Biacore CM5 Sensor Chips. CM5 sensor 
chips are designed for use in immobilizing proteins using EDC/NHS amine linking 
[43]. We typically linked the AChBP directly to the chip surface although we also 
used chips cross-linked with anti-Flag antibody to capture AChBP. The 
carboxymethyl dextran surface of a Biacore CM-5 chip was first activated by 
injecting a 1:1 ratio of 0.4 M EDC and 0.1 M NHS for 14 minutes at a flow rate of 
10 jal_/min. Purified AChBP was diluted to 68 |ag/mL in 10 mM sodium acetate, 
pH 4.0, and was injected for 10 minutes to achieve an optimum density. This 
method was optimized by varying pH and injection time using standard Biacore 
methods. The remaining activated surface groups were blocked with 1 M 
ethanolamine, pH 8.0. AChBP density was approximately 8000 resonance units 
(RU). Anti-Flag affinity chips were made using a similar procedure.
AChBP purified from the Sigma His-Select columns or eluted from 
polyacrylamide gels was directly identified using the anti-FLAG chip, verifying the 
accessibility of the Flag tag on the AChBP protein.
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3.2.5.1 Binding of ligands to SPR-AChBP biosensor.
AChBP was immobilized on one or more of the four available flow cells on 
the Biacore CM5 chip. Another flow cell (typically flow cell 1) served as a control 
cell. To prepare the control cell, the surface was activated with EDC/ NHS and 
then blocked with ethanolamine. All SPR data were determine by subtraction of 
the sample cell (containing AChBP) -  the control cell (ethanolamine blocked 
surface). This eliminates effects due to buffer effects on refractive index and 
non-specific binding to the chip surface. A series of nicotinic acetylcholine 
ligands were evaluated to test the functionality and sensitivity of the AChBP 
prepared SPR chip (dTC, physostigmine, galanthamine). A concentration series 
of each compound was injected to allow for determination of accurate kinetics. 
Duplicate samples of ligand were injected for 120 seconds at a flow rate of 50-75 
pL/min. Dissociation of ligand from immobilized AChBP was monitored for 2-5 
minutes. After dissociation, 10 mM Glycine, pH 2.5 was injected for 60 seconds 
at a flow rate of 50 pL/min to regenerate the surface. After regeneration, a 
stabilization time of 60 seconds was allowed between samples. Mass transport 
tests were also included in the analysis of all the compounds.
3.2.5.2 SPR biosensor data analysis.
Responses observed on a reference surface were subtracted from the 
binding responses obtained from the reaction surfaces. The average responses 
from buffer injections (0-concentrations) were also subtracted to remove 
systematic effects. Data were analyzed using BIAevaluation software, version 
3.0. Kinetic rate constants were determined by global curve fitting using 
standard Biacore 1:1 binding models and non-linear regression techniques 
(BIACORE AB, Uppsala, Sweden).
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3.2.6. Preparation of Microcantilever sensors.
Microcantilever experiments were developed and executed by Dr. Ji’s 
laboratory at the Institute for Micromanufacturing, Louisiana Tech University, 
Ruston, Louisiana (Gao et al. [35]). These experiments used commercially 
available silicon microcantilevers (Veeco Instruments). The dimensions of the V- 
shaped silicon microcantilevers were 180 pm in length, 25 pm in leg width, and 1 
pm in thickness. One side of these cantilevers was covered with a thin film of 
chromium (3 nm) and followed by a 20-nm layer of gold, both deposited by 
electron-beam evaporation. The uncoated side of the commercial microcantilever 
was silicon with a 12-19-A-thick, naturally grown Si02 (native oxide) layer. All the 
chemicals were used as received from Sigma-Aldrich. Proteins were immobilized 
on the gold side of the microcantilevers.
The most commonly used functional groups for attachment of bioreceptors 
are carboxyl and amino moieties [35], which are usually introduced on the 
microcantilever by exposure of the gold surface to the corresponding amino or 
carboxyl groups containing thiol compounds. The thiols form a monolayer on the 
gold surface through a well-known self-assembly process. After monolayer 
formation, the bioreceptors are conjugated on the surfaces through crosslinking 
reagents. One of the most widely used cross-linking procedures uses 1 -ethyl-3- 
(3-dimethylaminopropyl)carbodimide hydrochloride (EDC) and N-hydroxy- 
succinimide (NHS) to activate the surface (Figure 3.5). While widely used for 
multiple sensor devices, it has often been observed [44] that microcantilevers 
modified by a typical EDC/NHS process either did not deflect ligand when 
exposed to analyte or did not generate reproducible results. This poor 
performance of the microcantilever has been postulated to be due to either low 
packing density or defective surface coatings.
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Figure 3.5: Surface conjugation chemistry of proteins on gold surface using the EDC/NHS pair. 
From Gao et al [35].
Recently, Wang et al [45] investigated the surface characteristics of the 
amino and carboxyl topped monolayers generated from thiol compounds and 
observed unwanted particles on the surfaces. They further suggested the 
coexistence of trifluoroacetic acid (CF3COOH) with the thiols during SAM process 
for a smoother and cleaner surface. From these observations, it is reasonable to 
hypothesize that the unwanted particles inhibit the EDC/NHS crosslinking 
process. Removal of the particles on the surface prior to activation should 
improve microcantilever performance. Dr. Ji’s laboratory utilized an improved 
cleaner protocol (see section 3.2.6.1) to improve the performance of their 
microcantilever system.
3.2.6.1. A new method of microcantilever surface modification.
Dr. Ji’s laboratory [35] reported the effect of a clean monolayer surface (in 
which CF3COOH has been incorporated) on microcantilever sensing 
performance, focusing on protein-based sensors. Two methods of 
microcantilever preparation are discussed. The first, ‘Method A,’ is the standard 
method, which is found to be inferior to ‘Method B,’ the new method utilizing 
CF3COOH.
A typical EDC/NHS surface procedure (Method A) for protein 
immobilization is the following: The microcantilevers were thoroughly cleaned
with piranha solution and rinsed with water. The microcantilevers were then 
immersed for a 15-hour period in a 1 mM solution of 11-mercaptoundecanoic 
acid (MUA) in ethyl alcohol (EtOH), followed by rinsing in ethyl alcohol. Next, the 
microcantilevers were immersed in a 0.05 M 4-morpholine-propanesulfonic acid 
(MES) buffer solution containing 100 mg/ml of EDC and 100 mg/ml of NHS (pH = 
6.8) for 30 minutes at room temperature, and then immersed in a 2 mg/ml_ 
proteins in MES solution for 3 hrs, followed by rinsing in the MES buffer solution.
In the modified approach (Method B), the first monolayer formation 
process was modified by adding 0.2 ml_ of CF3COOH in the 1 mM solution of 
MUA in ethyl alcohol solution mentioned above. After 15 hours immersion in this 
solution, the microcantilevers were washed with EtOH, 10% (v/v) NH3-H20/Et0H, 
and then EtOH. The remainder of the procedure was the same as described 
above for Method A.
3.3 Biosensor results and discussion.
3.3.1 AChBP expression and characterization.
Quantification of protein concentration by Lowry assay (data not shown) 
indicated expression levels of approximately 1-4 milligrams AChBP per litre of 
culture medium collected from the 600 cm2 culture dishes. Non-denatured 
polyacrylamide gel electrophoresis (PAGE), (Figure 3.6) showed a distinct band 
of protein equivalent to a molecular weight of about 150 kD. SDS-PAGE 
conducted under denaturing conditions yielded a clear band of protein equivalent 
to about 30 kD. These molecular weights are consistent with literature values for 
AChBP and indicate the secreted protein assembles correctly with a pentameric 
structure.
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Figure 3.6. Acrylamide gel of AChBP. Denatured: A single, 7.5% polyacrylamide gel, Denatured 
(SDS): UT is a typical fraction from untransfected cells. Lanes 1-3 are typical of AChBP- 
transfected cells; the AChBP protein migrates to a region between 25 and 37 kD; lane “Std” 
contains BioRad Kaleidoscope standards; sizes in kilodaltons (kD) are indicated. Non-denatured. 
A second, 12% polyacrylamide gel, Non-denatured (no SDS): Lanes labelled “Std” are BioRad 
Kaleidoscope standards; sizes in kilodaltons (kD) are indicated. UT is from untransfected cells; 
Lanes “4” and “5” are from AChBP-transfected cells. The AChBP protein migrates to a region 
equivalent to almost 150 kD. Gels were stained with coomassie blue stain (BioRad). Some lanes 
were removed to save space.
3.3.1.1 Characterization of dried/reconstituted AChBP.
AChBP was dried as described in section 3.2.3 above. Reconstituted 
protein and freshly prepared protein (in solution) were compared to determine if 
the vacuum drying process had any observable effect on protein function. 
Reconstituted protein yielded similar Lowry results (100% recovery of total 
protein) and produced identical binding data using the SPA assay when 
compared to proteins that had not been dried (figure 3.7). We evaluated 
reconstituted protein immediately after drying and after several months of 
storage. Sodium dodecyl sulphate (SDS) and native (non-denatured) 
polyacrylamide gel electrophoresis (PAGE) were performed on the products, and
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the results were consistent with those from freshly eluted samples (data from 
dried samples not shown).
Figure 3.7. Effects of drying on AChBP binding kinetics. Concentrations of AChBP and 3H- 
(+)Epibatidine (epi), observed Kd and Bmax for each experiment, plus or minus standard deviation 
SD (except in graph D, where the 95% Cl is given instead of SD, and R2 for each graph are 
indicated. Dotted lines indicate 95% confidence intervals (Cl). The nonspecific binding signal was 
40±10 cpm at 1.0 nM, and was ignored in A-C. A. AChBP was eluted in 0.1% ascorbic acid and 
stored for about 3 weeks before removal of imidazole and use for SPA. This is the freshest 
AChBP for which we have good Kd data; However, this age should not be considered 
problematic, based on Hansen et al [42], B. After drying AChBP by the method described above. 
This AChBP was from the pooled sample that was to be used for microcantilever work. The Bmax 
is probably low (compared to C) because the AChBP was not allowed to dissolve fully before 
dilution. The observed lower Kd is probably a related artefact (note, however, that this Kd 
difference is not statistically significant). C. represents the pooled AChBP after storage of one 
year. Note similarity of Kd and Bmax to graph A. D. Counting efficiency of this method is about 
10%, based on given epi activity of 53.0 Ci/mmol.
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3.3.2 Binding Affinity of nAChR ligands to the AChBP by SPA.
Scintillation Proximity Assay (SPA) proved to be a fast, effective way of 
determining binding properties of various ligands to the AChBP. Pharmacological 
data compares well with data for previously expressed AChBP’s [3], [42],
Table 3.1 shows the binding of a series of nicotinic acetylcholine receptor 
ligands with the AChBP prepared by the methods described above. Data were 
obtained using the SPA assay. The table includes results obtained in our assay 
in comparison to those obtained previously by Smit et.al. and Hansen et al. Smit 
and Hansen expressed AChBP in two different expression system (yeast and 
HEK293 cells).
Table 3.1. Our AChBP SPA results compared with literature. Data shown are Ki values extracted 
from the indicated published reports (columns 2-3) or determined in this study (column 4) using 
3H-epibatidine as the radioligand.____________ ______________________________________________
Compound Smit et. al. 
(2001) [3] 
(Yeast)
Hansen et al.
(2002; 2004) [25, 42] 
(HEK293)
K j values for 
inhibition of 
3H-epi binding
a-bungarotoxin 2.6 ± 0.6nM 1.8 nM 3.6 nM
d-tubocurarine 93 ± 3 nM 150 nM 13.6 nM
Nicotine 98 ± 25 nM 86 nM 47 ± 5 nM
Epibatidine 1.4 ±0.1 nM 0.16 nM 0.12 ± .01 nM
Acetylcholine 4.2 ± 1.1 pM 0.89 pM 1.6 ±0.1 uM
Serotonin 269 ± 67 pM Not available 91 ± 15 pM
Little difference was observed between expression system except for 
acetylcholine and epibatidine. Smit observed a 4.7- fold lower affinity binding for 
acetylcholine and an 8.8- fold lower affinity for epibatidine using the yeast 
expression system when compared to the HEK293 system. Our data was 
obtained using expression in mammalian HEK293 cells and is comparable to 
Hansen et al. The most substantial difference in affinity between our data and 
Hansen’s was with d-tubocurarine. We observed an 11- fold higher affinity for 
dTC in our system. Differences in binding affinities are likely due to small 
differences in the experimental conditions although the specific affect of the
expression system on nicotinic agonists suggests that differences in post- 
translational modification may be slightly altering receptor mechanism. While the 
AChBP is not a ligand gated ion channel, it has been shown that conformational 
changes on binding of agonists do occur and that the protein likely shifts from a 
low affinity to high affinity agonist binding conformation. The similarity of our data 
to that obtained by Hansen et al validates the SPA as a sensor platform and 
demonstrates the successful production, synthesis, storage and attachment of 
the AChBP. The SPA technique is significant since it provides a rapid, low cost 
and easily accessible sensor platform for high throughput analysis. This 
approach is utilized to evaluate serotonergic ligand binding on the AChBP in 
chapter 4 of this thesis.
3.3.3 Binding of nAChR ligands evaluated by SPR.
To evaluate of the performance of the AChBP in Surface Plasmon 
Resonance (SPR) assays, purified AChBP was immobilized on CM-5 SPR chips 
using the EDC/NHS approach. Crosslinking of the AChBP yielded immobilization 
levels of approximately 3000 RU; sufficient for analysis of ligands over 200 amu. 
Figure 3.8 shows a series of sensorgrams obtained in a typical SPR experiment 
to determine binding kinetics of dTC to a CM-5/AChBP surface. dTC produced 
a maximum response of 100 RU. Typically, a response of 10-20 RU is sufficient 
for accurate determination of rate constants. At lower concentrations of dTC 
(<100 nM) the rate of binding was sufficiently slow to determine association 
rates. Dissociation rates were also easily determined from this data. The 
binding of dTC to the CM-5/AChBP surface illustrates the use of the AChBP as a 
molecular biosensor.
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SCL£
Figure 3.8. Resonance Units (RU) vs. time (seconds) for six concentrations of dTC. Sensor was 
prepared as described in section 3.2.
Table 3.2 shows preliminary data for SPR experiments. Binding of dTC to 
AChBP as determined from competition assays is easily accomplished with SPA 
since it competes for the same binding site as 3H-epibatidine (see table 3.1 
above). The data from both assays are comparable (12 nM using SPR and 13 
nM using SPA) demonstrating the consistency of the two approaches. For other 
ligands, such as the nicotinic modulators galanthamine and physostigmine, 
competition assays are not easily evaluated using radioligand binding since 
these allosteric modulators exhibit a complex modulatory mechanism that only 
partially alters binding of 3H-epibatidine. A better approach to this type of ligand 
would be a label free binding assay such as SPR. Galanthamine and 
physostigmine were also testing using the SPR approach and the data are also 
shown in Table 3.2. Their detection on SPR shows one of the unique advantages 
of this biosensor detection system.
Since this is the first use of SPR with the AChBP, no direct comparison is 
possible with previous studies; however, dissociation data can be compared to 
values obtained for these compounds using radioligand binding assays. In 
addition to dTC, dissociation constants also agree well with functional studies for 
galanthamine and physostigmine. Our result validates the use of the AChBP as 
a molecular sensor on SPR surfaces. The two primary advantage of the SPR
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technique are 1) It provides association and dissociation data for the test 
compounds and 2) it provides label free evaluation of binding to any binding site 
on the protein.
Table 3.2. SPR preliminary data. Kd is the equilibrium binding constant, ka and kd are on- and off- 
rate constants, respectively, Chi2 is a measure of how well the data fits the graph (lower is 
better). * indicates binding affinity obtained on Aplysia AChBP by inhibition of 3H-strychnine, from 
Hansen et al [46]. _____________ __________ ____________ ___________ ___________ ____________
Compound Kd ka
(1/Ms)
kd (1/s) Chi2 Kd
literature
M.W.
(g/mol)
d-tubocurarine 12.0 ±4.1 
nM
2.06e9 25.2 5.26 150nM
[42]
609.7
Galanthamine 1.6 nM 7.5e4 1,23e-3 15.3 1 ,5|jM* 287.4
Physostigmine 5.7 nM 5.87e3 3.36e-3 0.716 n/a 275.3
3.3.4 Binding of nAChR ligands to AChBP modified MC sensors.
Microcantilevers (MC) represent a novel approach to biosensor 
applications and are currently in a much earlier state of development then SPA 
and SPR. They have the advantage of low cost and high sensitivity but currently 
require more user expertise than other the other two techniques. To investigate 
the use of the AChBP on microcantilevers, we developed a collaboration with Dr. 
Hai-feng Ji at Louisiana Tech University in Ruston LA (Dr. Ji has recently 
relocated to Drexel University, Philadelphia PA).
Scanning electron micrographs of protein immobilized on microcantilevers 
are shown in figure 3.9 below. Horseradish peroxidase (HRP) and AChBP (not 
shown) were immobilized on the microcantilever surface using an EDC/NHS 
crosslinking protocol similar to that used on the SPR surfaces. Methods A and B 
differ in the type of surface preparation performed prior to AChBP (or HRP) 
immobilization. The denser packing apparent in the lower right figure provided 
an increase in sensitivity to detection of ligand binding to the AChBP. This 
increase in sensitivity is significant and is an important contribution of Dr. Ji’s 
research.
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Figure 3.9: SEM images of MC surfaces prepared using two methods. Bottom images show the 
new method. On the left are images taken before the addition of protein; the difference at this 
stage is subtle. Note the denser packing with the new method (B) after the addition of protein, at 
right (Horseradish peroxidase (HRP) in this case- but the effect was the same with AChBP). 
Images from reference [35].
Figure 3.10 below shows the bending response of AChBP modified 
microcantilevers in terms of the size of the deflection over exposure time to 10 
I^ M acetylcholine on these two different surface preparations. Method B 
employed a cleaning protocol to remove particles attached to the microcantilever 
surface prior to immobilization of analyte protein. The improved preparation 
method B provides not only an increased sensitivity but better response 
characteristics; The Langmuir adsorption model produced a better fit of the 
deflection-time profile of microcantilever B compared to A. The improved 
bending response afforded by Method B is likely the result of tighter packing of 
proteins on the microcantilever surface as suggested by the SEM data (Figure 
3.9). While it is possible that this close packing of an allosteric protein such as
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AChBP might interfere with the proteins function, these data confirm that the 
protein continues to bind ligand under these conditions.
Time, s
Figure 3.10. Bending response as a function of time. From Gao et al, [35]. Bending response as 
a function of time of AChBP coated microcantilevers prepared using Methods A and B, on 
exposure to 10 pM acetylcholine (Ach).
To determine the performance of the AChBP modified microcantilevers in 
determination of binding kinetics, a concentration series was tested for both the 
agonist acetylcholine and antagonist dTC. Figure 3.11 shows equilibrium 
bending of AChBP MC’s exposed to acetylcholine (A) and cttubocurarine (B). 
Acetylcholine produced large bending amplitudes at concentrations near its 
reported Kd for AChBP binding and a Kd of 4.0 ± 2.4 pM can be estimated from
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this data. dTC, in contrast, did not produce large amounts of bending at 
concentrations near its reported 12 nM Ki value. It has been suggested that 
proteins undergoing conformational changes produce larger bending amplitudes 
when packed tightly on the chip surface. The sensitivity to the agonist 
acetylcholine may be due to the effects on surface stress caused by the 
conformational change induced by an agonist. dTC is thought to simply compete 
for the agonist binding site without producing a conformational change. The 
binding of dTC may produce lower bending amplitude because it has a smaller 
effect on protein conformation. The bending at higher concentrations (1 jaM -1 
mM) could be due to non-specific binding of dTC to the surface. The ability to 
differentiate between agonist and antagonist effects using microcantilever 
sensors is significant since this is not possible with other binding methods and 
currently requires much slower functional assays. Further study using different 
agonists and antagonists as well as partial agonists will be needed to confirm this 
data.
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Figure 3.11. Bending response vs. time for AChBP microcantilevers (MC). Analytes acetylcholine 
and d-tubocurarine (d-tubocurare, dTC) were dissolved in 0.01 M phosphate buffer, pH 7.2 (A 
and B respectively). The MC’s were exposed to the indicated concentrations of analytes. 
Deflections are as follows. Acetylcholine: 0.001 pM -  12 nm, 0.10 pM -  25 nm, 1.0 pM -4 0  nm, 
10 pM -  96 nm. dTC: 0.1 nM -  2 nm, 1.0 pM -  21 nm, 1.0 mM, 71 nm.
3.3.4.1 Special acknowledgements for microcantilever assays:
This work was supported by NSF Sensor and Sensor Network ECS- 
0428263. H. Gao thanks the Chinese Scholarship Council For financial support. 
Schulte and Harms-Smyth thank the NIH Alaska INBRE program for financial 
support.
3.4. General Conclusions.
The primary goals of this portion of this thesis were to determine if the 
AChBP could be attached to biosensor surfaces yet remain active so that binding 
of ligands can be detected. A secondary goal was to evaluate the
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appropriateness of each biosensor platform for different types of ligands. This 
study had the following objectives as described in Chapter 1:
1 . Develop an expression and purification scheme for the AChBP that permits 
rapid purification of sufficient quantities of protein.
2 . Determine the storage qualities of the AChBP in solution and identify ways of 
stably storing the protein over a long time period (months).
3. Determine the functionality of the receptor on three biosensor platforms -  
Surface Plasmon Resonance, Scintillation Proximity Assay and 
Microcantilevers.
4. Determine the sensitivity and stability of the AChBP on each of the platforms 
tested in Objective 3.
The HEK293 expression system described here produced sufficient 
quantities of the AChBP protein to enable testing of all three target sensor 
systems. While the expressed protein was a fusion protein composed of an N- 
terminal Flag epitope tag, the AChBP coding sequence and a C-terminal 6X His 
sequence, these alterations had no apparent effect on the stability and function 
of the protein. The protein expressed in a pentameric quaternary structure and 
binding affinities were similar to previously published AChBP values expressed in 
the HEK293 cell line. An improvement in the storage and handling of the AChBP 
protein was the discovery that the protein could be easily dried and reconstituted 
without lack of activity or alteration in ligand binding.
The AChBP protein was easily immobilized on all three sensor surfaces 
and performed well in determination of binding kinetics. A comparison of the 
three sensor surfaces reveals differences in the applicability and sensitivity of 
each. The SPA assay was the preferred method for evaluation of competitive 
ligands since it offered low price, no molecular weight limitations and was easily 
amenable to multiwell plate assays. The quantity of protein required was
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extremely low and the results were consistent with previously reported data. The 
use of a radioligand was the primary disadvantage as well as the requirement 
that the competing ligand must alter the binding affinity of the radioligand. This 
second limitation prohibits discovery of novel compounds that may alter receptor 
function by non-competitive mechanisms.
Protein immobilization on SPR chips using the EDC/NHS method was 
very successful and now being used by others in the lab to evaluate allosteric 
ligands on the AChBP. The primary advantages of this method were its ability to 
detect binding of non-competitive ligands and the potential for screening libraries 
of non-labelled compounds and natural products and the ability to obtain rate 
constants for both on and off rates. A serious disadvantage of SPR was its 
inability to determine kinetics for low molecular weight compounds due to its 
reliance on molecular weight detection.
The microcantilever experiments suggested a number of intriguing 
possibilities for high-throughput screening. Although not described in this thesis, 
Dr. Ji’s laboratory is currently working to develop large microcantilever arrays 
with piezoelectric detection. Our data shows that the AChBP can be used to 
produce a viable sensor surface using microcantilevers and can potentially be 
used in this type of arrays to permit rapid screening of multiple receptors at one 
time. It is this ability to develop an array of receptors that has driven the two 
projects described in this thesis. By demonstrating the ability of the AChBP 
modified microcantilevers to detect acetylcholine and to permit determination of 
accurate binding affinities, we have laid the groundwork for developing these 
arrays. As discussed in the next chapter, it seems likely that the AChBP can be 
modified to create proteins with affinities similar to LGIC receptors other than the 
nAChR. These modified proteins can be added to the detection arrays to permit 
evaluation of a single drug molecule on multiple receptors simultaneously.
Another significant find in the microcantilever study is the discovery that 
agonists produce larger bending amplitudes than antagonists. “Conformational-
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change based biosensing” would provide a new way to obtain functional data 
using a chip based, high-throughput system.
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Chapter 4: Binding of serotonergic ligands to the AChBP
4.1 Background and Hypotheses.
Chapter 3 discussed the expression, purification and characterization of 
the AChBP developed in this project. The AChBP was successfully utilized as a 
biosensor protein using SPA, SPR and microcantilever sensors. While a useful 
protein for nicotinic ligands, as it currently exists, the AChBP is unlikely to be a 
useful biosensor for other LGIC ligands. The LGIC family is large and contains at 
least four different receptor subfamilies including GABA, Glycine and Serotonin in 
addition to nicotinic acetylcholine receptors. It would be very helpful for drug 
screening applications if each of these families had a soluble homolog like the 
AChBP. Unfortunately, no proteins of this type have been discovered. An 
alternative approach to discovering natural proteins similar to other LGIC 
receptors is to engineer them using the AChBP as a lead molecule.
As described in Chapter 1, a principal hypothesis of this thesis is that the 
AChBP can be engineered to selectively recognize different classes of LGIC by 
mutating key binding site amino acids in the AChBP to corresponding amino 
acids of the target LGIC receptor. In this chapter, the interaction of serotonin 
type 3 receptor (5-HT3R) ligands with the AChBP is investigated. This is the first 
step in developing a soluble homolog of the 5-HT3R. No data of this type have 
been determined previously for the AChBP despite the fact that it was used 
extensively as a template for generating ligand-docked computer models of the 
5-HT3R.
4.1.1. Modelling of LGIC’s based on AChBP.
Alignment of the AChBP sequence with the 5-HT3AR amino terminal sequence 
reveals (figure 4.1, [27]) significant sequence similarity (about 20% similarity 
[22]). Using an alignment similar to figure 4.1 and the crystal structures of the
58
AChBP, several homology models of the 5-HT3AR binding site have been 
developed [22, 23, 32, 33, 47, 48]. From these models, ligand-docked models 
have been developed and tested using site-directed mutagenesis. Both 
antagonist and agonist binding models have been proposed. Antagonist models 
have focused on the classical 5-HT3R antagonist granisetron and the non- 
classical antagonist Lerisetron. Agonist models have focused on the full agonist 
5-HT and the partial agonist /77CPBG (structures in Figure 4.7, section 4.3).
B-Loop ( mouseS-HTjjR S132-I190) C-Loop: <m5-HT3AR, E225-M237)
AChBP R I K I G S W T H H S R  E l S V T Y S C C  P E A Y E O V
m5-HT3AR S L T F T  S W L H T  1 Q D I E - F S i D I S N S Y A E M
h5-HT34R (Identical to  mouse) E -  F S M E S S  NS  Y A E M
D-loop: (m5-HT^R. T 8 6 -  W102> E-Loop: (m5-HT3AR Y 141-Y 153 )
AChBP DVVF W Q Q T T W S D R T L A W - P Q L A R V V S D G E V L Y M
m5-HT3AR TTY I W Y R Q Y W T D E F L Q W Y -  - - V Y V H H R G E V Q N Y
h5-H T„R (Identical to mouse) Y - - - V Y 1 R H Q G E V Q N Y
A-loop: (mouse 5-HT-4R 114-1301 F-loop: (mouse 5-HTw R 195-212}
AChBP S V P I S S L W V P D L A A Y N - - S V D P T T E N  S D D S E  Y F S Q Y S
m 5-H T„R SI  P T D S I W V P D  1 L I  N | F W - R S P E E V R  S D K S  1 F 1 N Q - G
h5-HT34R (Identical to mouse) W -  R L P E K V K  S D R S V  F M N Q - G
Figure 4.1: Sequence alignment of binding loops in AChBP and 5-HT3AR’s.
Aligned sequences: LS AChBP, murine 5-HT3AR (m5-HT3AR) [33], and human 5-HT3AR (h5- 
HT3AR)[27], The underlined amino acid residues indicate their significance (mutations to alanine 
have a ten-fold or more effect on binding) for binding to agonist (blue), antagonist (red), lerisetron 
+ agonist (purple) & agonist + antagonist (green). Note that colored residues in the B-loop, D-loop 
and F-loop may be important to agonists and lerisetron as well as antagonists, but data to this 
effect is not available.
4.1.2. Binding models for the 5-HT3aR antagonist granisetron.
Several recent models describing binding of granisetron to the 5-HT3AR 
have been proposed by the labs and collaborators of Sarah Lummis [13, 32, 33, 
49] and Marvin Schulte [22, 23, 48]. In the majority of the recent models from 
both groups [22, 49] granisetron docks within 4-5 A of both Y234 and W183 (see 
figure 4.2). Some part of granisetron is typically (except in one of the Lummis
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models) docked between the superficially-located C-loop Y234, and the deeper B 
loop W183. Residues W90, Y153 and D229, which also seem to be involved in 
binding granisetron, are also within 4-5 A of granisetron in most of the models. In 
each of the models, granisetron lies adjacent and parallel to the backbone of the 
B-loop of the primary (+) face, with the C-loop forming something like an open 
“lid” as mentioned earlier.
The Lummis models [49] were divided into three classes, which together 
placed a total of 26 residues close (<5 A) to granisetron, of which 8 were 
common to each of the models. Of these 8, W90 (D-loop, complementary (-) 
face) and T179 (B-loop, (+) face) are probably important to binding granisetron, 
according to mutagenesis studies. Two groups of Lummis models (termed A and 
B) have either the azobicyclic structure (group A) or the aromatic rings (group B), 
of granisetron situated between critical aromatic residues W183 and Y234.
Group C models place granisetron close to several F-loop residues but not close 
to W183 or Y234, but perpendicular to the B-loop. Group C models were 
tentatively ruled out by the authors based on lack of support by mutagenesis 
data. The evidence presented for model group B (the authors’ favourite) over 
model group A is not convincing (Y153 hydrogen bonding is implicated, and 
previous research is sited, but the Y153F mutation which the authors tested 
indicates that Y153 plays its role possibly partly via its aromatic ring).
Joshi et al. [22] investigated the binding (docking) of granisetron to an 
agonist-free (lid-open) model of the 5-HT3aR, which utilized the recently-obtained 
high-resolution nAChR structure by Unwin et.al [5]. The authors indicated two 
separate sets of binding sites for this molecule, and both appear to be important. 
The first, “B” position (in one of two orientations - B1 or B2) orientations), acts as 
a pre-docking site, and the second “A” position (in either of two orientations - A1 
or A2) is the final high affinity binding site for granisetron. The two-site theory 
was adopted because granisetron is not long enough to bind to residues in two 
regions of the receptor determined by mutagenesis as critical to 3H-granisetron
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binding at the same time (see section 4.3, figure 4.6 for structure of granisetron). 
Like in the Lummis models, these models have either the azobicyclic structure 
(orientation B1 and A2) or the aromatic rings (orientation B2 and A1), of 
granisetron situated between critical aromatic residues W183 and Y234 (in other 
words, deep from loop C). 3H-granisetron is thought to pre-dock utilizing 
residues H185, D189, L184 and possibly W183 then move into the final high 
affinity site where it is postulated to utilize interactions to W90, W183, Y234,
D229 and E129. Of these residues, W183, H185, Y234 and D229 are thought to 
be most important.
Figure 4.2. Conserved structural features of the binding sites. These pictures are derived from 
crystal structure of AChBP (PDB entry 1I9B [27]) using DeepView. Upper right: Side view of the 
AChBP pentamer. Upper left: the binding cleft is formed by two adjacent subunits. Loops A-F are 
named in red. Bottom: everything is removed except the binding loops A-F, for clarity. The figure 
on the lower right would be deep to the figure on the lower left, as indicated by the upper left 
figure. Arrows indicate the side chain positions where side chains are shown, and AChBP 
residues are given in parentheses- example “E: Y143 (R)” means binding loop E, 5-HT3AR 
position of Y143, AChBP residue is arginine (R).
Of the key residues implicated in the Lummis and Joshi models, W183 
and H185 in the B-loop, Y234 in the C-loop and W90 in the E loop are all 
conserved in the AChBP. H185 in the Joshi model is also conserved and only a 
moderate substitution at D189 is present in the AChBP (E- Glutamate). Thus all 
of the key residues thought to interact with granisetron in the 5 -HT3R are 
conserved in the AChBP. The primary difference in key residues between the
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AChBP and 5-HT3R is D229 (5-HT3R). This residue is generally aligned with the 
first of two vicinal cysteines in the C-loop of the AChBP. These cysteines are 
thought to confer the correct structural orientation of the C-loop and thus 
mutation will alter the position of the key Y234 residue. In mutagenesis studies, 
mutation of D229 may alter binding of granisetron via a structural role rather than 
direct interaction. A comparison of the Joshi and Lummis models leads to the 
hypothesis that binding of 3H-granisetron to AChBP will be similar to the 5-HT3R. 
Small differences in a number of other potentially important residues present in 
the receptor models (for example E-loop residues Y143 and Y153) would be 
expected to produce only small decreases in 3H-granisetron binding affinity. With 
respect to Y143 and Y153, however, the models suggest H-bond interactions 
which would be conserved by the asparagine and methionine substitutions at 
these positions. Additional residues in the E and F loops (G147, V149, D204) 
which may also be important to binding site structure and positioning of less 
important residues in those loops are also conserved between the two receptors.
From either the Joshi or the Lummis models, but especially the Joshi 
model, one would expect to see binding of granisetron to AChBP; We 
hypothesized that the affinity for 3H-granisetron for both receptors would be 
similar based on the conservation of residues W90, W183, Y234, and their 
importance to granisetron binding in both sets of models. It is possible, of 
course, that a lack of conservation in a few less-critical residues could produce 
slightly weaker binding to the AChBP. Structural similarity of granisetron and 
other classical 5-HT3R antagonists would suggest that MDL72222 and 
tropisetron would also bind to the 5-HT3aR with similar affinities.
4.1.3. Binding models for 5-HT3AR agonists 5-HT and /wCPBG.
Alanine scanning mutagenesis has implicated the tyrosine residues Y143 
and Y153 in the E-loop, [50], F226 in the C-loop [23], and T179 and F180 in the 
B-loop [47] of the murine 5-HT3AsR, as particularly important to binding of 5-
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HT3R agonists. Alanine mutants at these positions result in at least a one 
hundred-fold decreases in agonist affinity, but only tenfold or less decrease in 
antagonist affinity. Selectivity of some mutations for full versus partial agonists 
have also been observed. Alanine mutations of 1228 and D229 (C-loop) 
decrease binding affinity of the 5 -HT3AR for 5-HT, but not /77CPBG. Y234F 
mutation of the 5-HT3AR results in 125- and 185-fold decreases in /77CPBG or 5- 
HT (agonist) binding respectively, but only an 11-fold decrease in 3H-granisetron 
binding. In addition to these agonist selective residues, several of those 
mentioned above for antagonists (Section 4.1.2) are also important to agonist 
binding and/or gating [47],
Reeves et al. [32] first used homology modelling based on AChBP (from 
the HEPES-bound AChBP crystal structure, [27]) to probe the docking of 5-HT to 
the 5 -HT3AR. Seven energetically favourable models were described. In three of 
these, the primary amine of 5-HT is situated in the lower (proximal to the 
membrane) part of the binding cleft, near W90, and the aromatic part is 
“sandwiched” between B-loop’s W183 and C-loop’s Y234 aromatic rings. The 
hydroxyl group of 5-HT appears in these first three models to be in a hydrophilic 
pocket formed by R92, Q151, and D229. In the fourth and fifth models, the 
primary amine of 5-HT is between W183 and Y234, the aromatic rings are in the 
lower part of the cleft, and the hydroxyl group is in a hydrophilic pocket formed by 
T179, E236, and N128. In these first five models, either the indole nitrogen- 
bound hydrogens (in models 1-3), or the primary amine hydrogens (models 4-5) 
form hydrogen bonds with the exposed S182 backbone carbonyl oxygen, so that 
the 5-HT nitrogens line up vertically along the B-loop, leaving the six-membered 
ring pointing right (models 1-3) or left (models 4-5). In the sixth and seventh 
models, the indole nitrogen is located toward the top of the cleft, but the primary 
amine is pointed toward the right (minus-face side) in model six, or left (model 
seven). In addition to those residues above, Y143 and Y153 can form hydrogen
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bonds of various lengths (most of which are fairly long, however) with 5-HT. The 
authors chose model 4.
More recently, Suryanarayanan et al [23] developed ligand-docked models 
for 5-HT, 2-Methyl-5-hydroxytryptamine (2-Me-5-HT), and m- 
Chlorophenylbiguanide (/77CPBG) binding to the 5-HT3AR; also using a homology 
model based on Brejc et al [27], A single binding orientation was determined for 
5-HT from these studies. 2-Me-5-HT bound in a similar orientation to 5-HT. Two 
modes of binding were determined for /77CPBG, one which placed /77CPBG in a 
different orientation from that of 5-HT (/77CPBG model 1), and one where the 
orientation was nearly the same as for 5-HT (/77CPBG model 2). In the 5-HT 
model and /77CPBG model 2, the primary amino and guanidino groups of 5-HT 
and /77CPBG respectively are intercalated between F226 and Y234 in the C-loop, 
and forms a salt bridge with E236. The aromatic group ring of 5-HT is involved in 
t t - t t  interactions with W183, while the hydroxyl group hydrogen bonds with D229. 
Y153 was found to be close (within 4 A) to 5-HT in this as well as the Reeves et 
al models, and can form cation-TT or hydrogen bond interactions with the 
guanidino group in /77CPBG model 1.
It should be noted that the AChBP crystal structure, upon which these 
agonist-binding models was based, is thought to resemble the closed- 
desensitized state rather then the open state of the 5-HT3AR. The desensitized 
state is thought to have a higher affinity for agonists than the open state. Since 
the true structural differences between open and desensitized states are 
unknown, models based on desensitized state binding may include structural 
errors.
A key receptor region in both binding of agonists and conformational 
change in the 5-HT3R is the C-loop. This region is thought to close over the 
agonist prior to channel opening. The C-loop region is highly variable between 
LGIC receptors that bind different classes of agonists. Since this is a highly 
variable region with little sequence homology between the AChBP and 5-HT3R,
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the C-loop sequences of the 5-HT3aR and AChBP are difficult to align. This 
places doubts on the structural/functional equivalency of AChBP residues to 5- 
HT3AR residues in this loop. It is true that the alignment shows great dissimilarity 
between human 5-HT3AR residues and AChBP residues in this loop, but there is 
also a lack of conservation between the 5-HT3AR’s of human and mouse. It has 
been proposed [22] that the C-loop of the 5-HT3AR forms a “lid” which closes 
(“lid-shut”) over agonists during binding, but stays open during binding to 
antagonists. Likely, then, a functional characteristic of an agonist is to induce the 
closing of this lid, and the closing of the lid is linked to the activated (channel 
open) state of the receptor. A closed lid would allow more interactions of agonists 
with the C-loop of the receptor, which accounts for mutagenesis and modelling 
data that implicate C-loop residues F226, 1228, D229, and E236 (there is no 
mutagenesis data available to indicate the importance or lack thereof of E236) in 
binding the agonist 5-HT, but not granisetron.
The above C-loop residues are not conserved in AChBP. Neither are the 
critical E loop tyrosines Y143 and Y153, although a small shift in the AChBP 
alignment would allow for a nearby tyrosine to align with Y153. 5-HT3AR Y234 
appears to be conserved, however, and E236 aligns with an aspartate (D) in 
AChBP. Because of the conserved B-loop residues mentioned above, it could be 
expected that 5-HT3AR agonists would bind to AChBP, but much more weakly 
than antagonists would.
4.1.4. Binding models for the 5-HT3AR antagonist lerisetron.
Lerisetron is structurally different than the other 5-HT3AR antagonists 
studied here in that it has a benzyl group protruding sideways from its aromatic 
part, it has no carbonyl oxygen, and it has a piperazine group instead of an 
azobicyclic group. Although it is often considered a special class of serotonergic 
antagonist, it does contain the basic antagonist pharmacophore: aromatic on one 
end, and an amine base on the other separated by a distance of about 9 A.
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Mutagenesis studies indicate that the E-loop tyrosines Y143 and Y153 on the 5- 
HT3AR are critical to its binding lerisetron [50]. From these mutational studies 
and a comparison of the granisetron and lerisetron structures, it might be 
expected that lerisetron would bind AChBP with an affinity somewhere between 
that of serotonergic agonists and classical antagonists.
4.1.5. Summary
Analysis of 5-HT3R data and ligand-docked homology models in 
comparison to the AChBP crystal structure data suggests that serotonergic 
agonists and antagonists will interact quite differently with the AChBP. We 
hypothesized that the serotonin antagonists granisetron, MDL-2222 and perhaps 
lerisetron would bind with high affinity to the AChBP, although possibly 10-100 
fold less tightly than to the 5-HT3R due to small substitutions of some interacting 
or structurally relevant amino acids. Serotonergic agonists, however, are 
expected to bind with much lower affinity at the AChBP due to large sequence 
dissimilarities between the AChBP and 5-HT3R in regions postulated to be critical 
binding areas for these ligands; particularly the C-loop and E-loop regions. In 
order to test these hypotheses, we evaluated the interaction of a series of 
serotonin agonists and antagonists with the AChBP. Our data largely support 
our hypotheses; however, the non-classical antagonist lerisetron was found to 
bind much more weakly than classical antagonists to the AChBP. These data 
provide insight into the reliability of ligand-docked models of the receptors and 
provide information for use in developing a serotonin binding protein.
4.2 Methods.
We used scintillation proximity assay to evaluate the binding of serotonin 
type 3 receptor (5-HT3R) agonists, partial agonists and antagonists to the 
AChBP. We expressed an AChBP fusion protein containing a 6X Histidine tag on
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the C-terminal, and a 3XFIag tag on the N-terminal under control of a CMV 
promoter. The sequence of the AChBP was determined from published reports 
and synthesized using commercial DNA synthesis. His and Flag tags were 
added to facilitate an affinity purification scheme as previously described. The 
protein was expressed in HEK 293 cells, and purified on Sigma His-Select nickel- 
EDTA columns. Chapter 3 of this thesis described this expression and 
purification and demonstrated the integrity of the expressed protein. Validation of 
the binding kinetics of this AChBP were also determined in experiments 
described in Chapter 3 and found in agreement with previously published data 
from cloned AChBP protein obtained from Lymnaea stagnatis.
SPA differs from conventional binding assays in that no filtering is required 
to separate bound and unbound ligand. This makes the procedure easier to 
automate and produces highly consistent results in a small amount of time. The 
primary drawback of the technique is the need for a radiolabelled ligand. Since 
radioligands are not available for all of the compounds evaluated here, 
experiments to determine the affinity for non-labelled compounds utilized 
competition assays. Typically 3H-epibatidine was used as the radioligand in 
these experiments.
4.2.1 Binding of 3H-epibatidine and 3H-granisetron to AChBP.
For 3H-epibatidine radioligand binding, a suspension of 0.1 mg beads per 
ml in phosphate buffered saline (PBS, see appendix 2), was incubated one hour 
with 2 mg/ml BSA, and 0.0125 nM AChBP. Three ml of this suspension was 
added to 4ml scintillation vials. Seven concentrations of 3H-epibatidine were 
used with concentrations increasing in three-fold steps from 0.004 nM to 3.0 nM. 
Control tubes containing no 3H-epibatidine were also included. Samples were 
capped and shaken for one minute then equilibrated for one hour at room 
temperature before counting. Typical Bmax values of 1000 counts per minute
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(CPM) were obtained, with a percent error of about 5%. The 3H-epibatidine 
binding curve is shown in figure 4.3.
[3H-epibatidine] (M)
Figure 4.3: Binding of 3H-epibatidine to AChBP. Dashed lines represent 95% confidence interval 
(95% Cl). Data shown were obtained by 7 different experiments using different preparations of 
AChBP.
For 3H-granisetron binding the binding assay was modified to use a higher 
concentration of protein (2.6 nM AChBP) due to the expected lower affinity of 3H- 
granesetron. Only 200 \i\ of beads/radioligand mix were required per sample. 
3H-granisetron concentrations were varied between about 1.0 nM and 240 nM. 
Nonspecific binding was determined in the presence of 1.0 M acetylcholine, and 
was subtracted. Incubation time was increased to at least two hours.
4.2.2 Competition assays.
3H-epibatidine (1.0 nM) was used as the radioligand in competitive binding 
experiments, with 0.025 nM AChBP, in 3 ml. Inhibitor concentrations ranged 
from 9- fold below the expected Ki to 9- fold above and were varied in 3-fold 
steps. Initial scouting, to estimate Ki values, used 10-fold steps in concentration
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beginning with 0.10 nM and increasing until the binding of (1.0 nM) 3H- 
epibatidine was either maximally inhibited or the concentration exceeded 1mM. 
Care was taken so that bound radioligand remained <10% of total ligand added. 
Final ligand concentration was calculated as Initial concentration - bound ligand. 
Competing ligand was added before the radioligand, and the mixture equilibrated 
for at least two hours prior to counting.
4.2.3 SPA data analysis.
Data were analyzed using Graph Pad Prism 4.0 software. The Kd values 
for 3H-Epibatidine and 3H-granisetron were calculated using the simple one-site 
binding model:
Equation 1 Y /Bmax = X  / Kd + X,
where X is radioligand concentration and Y is the fraction bound (measured as s 
counts per minute. For 3H-epibatidine, non-specific binding signal was <<10%, 
and was ignored. Non-specific binding of 3H-granisetron was linear with ligand 
concentration, and was determined in parallel experiments and subtracted.
For competition experiments, the fractional response remaining at each 
concentration of competing ligand was plotted against the ligand concentration. 
An IC5o value was determined from this data using Graphpad prism software and 
the following equation:
Equation 2  Y= 1 / (1 + 10(P°9(IC50^ X] *Hi"slope))
where X is the logarithm of the molar concentration of inhibitor ligand, and Y is 
fraction bound at a specific inhibitor concentration. An apparent Ki was calculated 
from the IC50 using the Cheng-Prusoff relation: Ki = IC50 * (Kd(epi)/[epi]).
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4.3 Results
Serotonin (5-HT), /77-chlorophenylbiguanide (/ttCPBG), 2-methyl-serotonin 
(2-Me-5-HT), phenylbiguanide (PBG), lerisetron, MDL72222, and tropisetron all 
competed with epibatidine for the primary binding site on AChBP, binding with 
affinities (Kj) ranging from 33 nM for the 5-HT3R antagonist tropisetron to 600 pM 
for PBG. 3H-Granisetron, which is structurally similar to tropisetron and can be 
inhibited by either MDL72222 or acetylcholine (data not shown), can therefore 
now also be assumed to bind to the primary AChBP site, bound with a Kd of 21.7 
nM (Figure 4.4, Table 4.1.). Table 4.1 (section 4.3.1) also compares the affinities 
acquired for the AChBP with literature values of the same compounds binding to 
the murine 5-HT3AsR-
4.3.1 Binding of 5-HT3R antagonists to AChBP.
Since granisetron is available in a radio-labelled form (3H-granisetron), 
binding could be determined directly. Figure 4.4 below shows binding of 3H- 
granisetron to AChBP-bound SPA beads. The apparent Kd for granisetron 
binding was determined to be 22 ± 1.4 nM. This is about 20 fold less than its 
affinity on 5-HT3Rs (1.0 ± 0.16 nM) and is within the range predicted by our 
analysis of the mutagenesis and structural data.
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[3H-granisetron] (M)
Figure 4.4:3H-granisetron binding to AChBP. 3H-granisetron binding was determined by exposing 
AChBP bound SPA beads to increasing concentrations of ligand. Non-specific binding was 
subtracted from total binding to obtain this data. Data from 4 experiments were fit to a one site 
binding model using non-linear regression and Graphpad Prism software. Dashed lines indicate 
the 95% confidence intervals. The data represent pooled data from four independent 
experiments.
Results of competition studies with other 5 -HT3R antagonists are shown in 
Figure 4.5 and summarized in Table 4.1. These data reveal differences in binding 
of tropisetron, MDL-72222 and d-tubocurarine similar to those observed for 3H- 
granisetron. Tropisetron binds about 30 fold weaker on the AChBP compared to 
its affinity for the 5-HT3R. MDL-72222 binds about 3.5 times weaker and d- 
tubocurarine only 2 fold weaker. Granisetron, MDL-72222 and tropisetron are 
considered part of the same structural family as granisetron and this data is 
consistent with our hypothesis (see figure 4.6 for structures), d-tubocurarine, 
although a different structural class is thought to utilize an aromatic-amino group 
pair of interactions similar to granisetron and so may be binding to a very similar 
group of amino acids.
72
x
CO
E
GO
m
1.2
1.0
0.8
0.6
0.4
0.2
0.0 b -
-15
■ Lerisetron 
a MDL72222
▼ Tropisetron
-10 -5
log [in h ib ito r] (M)
n
0
Figure 4.5: Inhibition of 3H-Epibatadine binding to AChBP by 5-HT3R antagonists. Data represent 
pooled results from 3 experiments. Kj values for compounds are as follows: tropisetron 33 ± 10 
nM, MDL72222 92 ± 20 nM, and Lerisetron 5400 ± 900 nM.
Table 4.1: Serotonergic antagonist binding to AChBP and 5-HT3R.
Kd and K data for AChBP (2nd column) were determined in at least three replicate experiments. 
5-HT3R data (3rd column) are literature values obtained using murine serotonin type 3A and 3AS 
receptors. Relative affinities (fourth column) indicate the affinity on the AChBP relative to the 5-
HT3R data in column 3 and were calculated by dividing column 3 by column 2.
Compound Kd or Ki ± SE 5-HT3R AChBP Kj/
(From this study) Kd or Kj ± SE 5 -HT3R Kj
(From Previous Studies)
Granisetron 22 ± 1.4nM (Kd) 0.96 ±0.16 nM 23
Tropisetron 33 ± 10 nM 1.1 nM 30
MDL72222 92 ± 20 nM 27 nM 3.4
Lerisetron 5.4 ± 0.9 ijM 0.8 ±0.19 nM 6700
d-tubocurarine 14 ±0.2 nM 6 ± 2 nM 2.3
Lerisetron is a non-classical antagonist for the 5-HT3R that contains 
structural features not found on classical agonists; namely the addition of a
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second aromatic group (Figure 4.6, below) Mutagenesis studies have indicated 
selective effects of 5-HT3R E-loop mutations on lerisetron compared to 
granisetron. Binding affinity for Lei isetron to the AChBP is 5.4 ± 0.9 |jM 
compared to its very tight binding to the 5-HT3R (0.8 ± 0.19 nM); nearly 7000- 
fold less potent. Based on the hypothesis that lerisetron binds similarly to 
granisetron, lerisetron would be expected to bind very tightly to the AChBP. The 
poor binding suggests a difference in the granisetron and lerisetron binding 
mechanisms.
Granisetron Tropisetron
Figure 4.6. Structures of the 5-HT3R antagonists in this study. Note that the amine nitrogens are 
basic and should be considered positively charged at pH 7, although this is usually not indicated, 
and is not indicated in the figure. Figure made using ChemWindow.
4.3.2 Binding of 5-HT3R agonists to the AChBP.
Serotonin (5-HT), 2-methyl-5-hydroxytryptamine (2-Me-5-HT), m- 
chlorophenylbiguanide (/77CPBG) and phenylbiguanide (PBG) represent two 
groups of agonists/partial agonists for the 5-HT3R (See figure 4.7 for agonist
a Lerisetron
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structures). The rank efficacy for all 4 agonists is: Serotonin>/77CPBG>PBG>2- 
Me-5-HT. Agonists for the 5-HT3R occupy a binding site that overlaps the 
antagonist binding domain thus agonists and agonists compete for binding to the 
receptor. A fundamental difference between agonist and antagonists is thought 
to be the ability of agonists to interact with the C-loop causing it to rotate down 
and “cap” the binding site. The open conformation (C-loop rotated out) is often 
termed the “lid open” conformation and the closed conformation (C-loop rotated 
down) the “lid closed” conformation. These terms should not be confused with 
the “open” and “closed” conformations of the integral ion channel. Rotation of the 
C-loop down to the lid closed conformation ultimately leads to channel opening. 
The movement of the C-loop to the closed position typically produces a higher 
affinity binding site for the agonist/partial agonist.
Figure 4.7. Structures of the 5-HT3R agonists in this study. Abbreviations are 5-HT, serotonin; 2- 
Me-5-HT, 2-Methyl-serotonin; /ttCPBG, /77-chlorophenylbiguanide; and PBG, phenylbiguanide. 
Note that the amine nitrogens are basic and should be considered positively charged at pH 7, 
although this is usually not indicated, and is not indicated in the figure. Figure made using 
ChemWindow.
5-HT mT.PRn
2-Me-5-HT
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As discussed earlier, we hypothesize that agonists will bind significantly 
more weakly to the AChBP due to differences between the AChBP and 5-HT3R 
sequences, primarily in C-loop residues (although other residues are also 
involved). To test this hypothesis, we evaluated 4 different 5-HT3R agonists 
(shown in figure 4.8 and tabulated in Table 4.2.)
Log[inhibitor] (M)
Figure 4.8. Inhibition of 3H-Epibatadine binding to AChBP by 5-HT3R agonists. Normalized data 
points from 3 experiments are plotted on a single graph and fit to a one-site competition model 
(See materials and methods).
Rank potencies for the 4 agonists tested were significantly different on the 
AChBP compared to the 5-HT3R (Table 4.2). On the 5-HT3R, rank potencies are: 
mCPBG > 5-HT > 2-Me-5-HT > PBG. For the AChBP, 5-HT, 2-Me-5-HT and 
/77CPBG were essentially identical in affinity with PBG about 6 fold less potent 
than the other three. This change in rank potencies was reflected in the relative 
affinities on AChBP versus 5-HT3R (Table 4.2). The largest differences were 
observed for mCPBG which was 33,000 fold less potent on the AChBP. 5-HT 
and 2-Me-5-HT were similar and PBG was the least effected. This weaker 
binding is consistent with our hypothesis that large structural changes in the C-
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loop region may produce significant differences in binding affinity for agonists.
The extremely large difference in binding of /77CPBG compared to PBG is 
somewhat surprising although it should be noted that the PBG is a far weaker 
partial agonist than /77CPBG.
Table 4.2. 5-HT3R agonists binding to the AChBP and 5-HT3R. Kd and K; data for AChBP (2nd 
column) were determined in at least three replicate experiments. 5-HT3R data (3rd column) are 
literature values obtained using murine serotonin type 3A and 3AS receptors. Relative affinities 
(fourth column) indicate the affinity on the AChBP relative to the 5-HT3R data in column 3 and
were calculated by c ividing column 3 by column 2.
Compound Kd or Kj ± SE
(From this study)
5-HT3R 
Kd or Kj ± SE 
(From Previous Studies)
AChBP Kj/ 
5-HT3R Ki
Serotonin 91 ± 15 |jM 74 ± 17 nM, 1200
2-Me-5-HT 120 ±40 |JM 150 ± 70 nM 800
/ttCPBG 100 ±20 uM 3.0 ± 0.55 nM 33,000
PBG 600 ± 200 mM 1.3 |jM 460
4.4 Discussion and Conclusions.
As we expected, all of the serotonergic ligands tested bound to 5-HT3R 
with higher affinity than to AChBP. However there were some important 
differences. This section discusses these differences and analyzes the 5-HT3R 
models.
4.4.1 Antagonist versus Agonist differences.
In general, 5-HT3R antagonists tend to have considerably higher affinity 
for the AChBP than the agonists (Table 4.1 and 4.2) In fact, antagonist affinities 
are reasonably close to the corresponding 5-HT3R affinities. This result is 
convincing evidence for the validity of 5-HT3R antagonist binding models based 
on AChBP (particularly those from the Lummis and Schulte labs). These results 
support the proposed role of the highly conserved residues in the B and D 
binding loops of the 5HT3R in binding antagonists. The E and C-loops which
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show differences between the two binding sites are likely to be responsible for 
the large difference between agonist and antagonist binding. Due to the 
significant structural difference between the C loops of the two receptors, it is 
likely that this loop is primarily responsible for the difference in comparative 
binding affinities for agonists versus partial agonists.
4.4.2 Interactions with serotonergic antagonists
3H-granisetron interacts with B-loop residues W183, H185 and D189 on 
the 5-HT3AR (Appendix 1) but little is known about how these residues interact. 
Two of the three residues are conserved and the third residue, D189, is 
substituted for another acidic residue, glutamate, on the AChBP. Given the 
relatively high affinity of AChBP for the antagonists granisetron, tropisetron, and 
MDL72222, which all contain the carbonyl oxygen from the Hibert 
pharmacophore, compared to lerisetron and 5-HT3R agonists which do not, it is 
tempting to implicate interactions involving that group. However this 
interpretation of the data should be approached with caution since such 
interactions might be overshadowed by the interactions of the C-loop with 
agonists, and by interactions of the N-benzyl group in lerisetron, as discussed 
above (section 4.3.1). More detail about this interaction could be inferred using 
site-directed mutagenesis and possibly a broader sampling of antagonists with 
varied structures.
4.4.3 Location of granisetron in the 5-HT3R binding site.
Joshi et al. [22] investigated the binding (docking) of granisetron to an 
agonist-free (lid-open) model of the 5-HT3AR. The authors indicated two 
separate sets of binding sites for this molecule, and that both appear to be 
important; the first, “B” orientations, act as way-in sites, then “A” orientations are 
final resting places for granisetron (see introduction for more detail). These 
results are consistent with this model, since they strongly indicate a very similar
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binding site for AChBP, despite the non-identical sequences of the two proteins. 
This is easier to explain by assuming that the residues important to binding 
antagonists in the 5 -HT3R actually make contacts with these antagonists. The 
Joshi model is the best one so far, since it explains the interactions with the 
highest number of important B-loop and other AChBP-conserved residues.
4.4.4 C- and E-loop interactions with agonists.
Afchlorophenylbiguanide ( /7 7 C P B G ) ,  and the other agonists tested 
(phenylbiguanide ( P B G ) ,  Serotonin (5-HT), and 2-Me-5-HT), all bind 
comparatively poorly to A C h B P .  The comparison of agonist versus antagonist 
data in table 4.2, taken with the degree of conservation of important residues, 
suggests that interactions of 5-HT with the C- and E-loops are indeed taking 
place in the 5-HT3AR more than in A C h B P ;  this strongly supports our agonist 
hypothesis and the models upon which it is based.
Interestingly, in comparing the partial agonist A77CPBG to the full agonist 5- 
HT, the decreases in affinity of AChBP compared to 5-HT3R are very different 
(33,000 and 1200, respectively). F226 is the only C-loop residue that is 
important to the binding of mCPBG, which is not conserved in AChBP. On the 
other hand, I228 and D229, in addition to F226, are both very important in 
binding 5-HT to the murine 5-HT3AR. From this information we would expect 
/79CPBG to be /ess specific than 5-HT to the 5-HT3AR, and yet we find the 
opposite is true. The lack of interspecies conservation, and the poor alignment, 
of the C-loops of 5-HT3AR’s and AChBP make interpretation of this data difficult.
It has been proposed [22, 51] that the C-loop of the 5-HT3AR and other 
cys-loop LGIC’s forms a “lid” which closes over bound agonists- “lid shut 
conformation,” but not antagonists- “lid open conformation.” X-ray 
crystallography studies have shown that AChBP does adopt “lid open” and “lid 
shut” conformations when binding some nAChR agonists and antagonists, 
respectively. Further, the C-loop is known to be flexible, and has been linked in
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cys-loop receptors to signal transduction (i.e. agonist-induced channel opening). 
Given this information, it seems likely that the AChBP C-loop adopts specific 
local structures, which may correspond to the conformational stability of the 
overall protein, and through this stability to binding affinity, when binding different 
serotonergic ligands.
It should be noted that it is not known which serotonergic ligands act like 
agonists with respect to the C-loop, and which act like antagonists on AChBP 
(note: “agonist” and “antagonist” are not truly proper terms here, because the 
AChBP is not a functional ion channel). In the future, crystal structures of 
serotonergic ligand-bound AChBP and energy minimization studies could be 
used to elucidate these structures and infer their effects on binding affinity.
4.4.5 Lerisetron binds weakly to AChBP.
The one exception to the strong-binding antagonist rule is lerisetron, a 
novel antagonist, which has a very high affinity for the 5-HT3R, 0.8 nM Ki, [50] 
but a 7000-fold increase in the Ki when binding to AChBP (Table 4.1 above). 
Mutagenesis data indicate that lerisetron interacts with Y142 and Y152 (Y143 
and Y153) on the 5HT3R, as do serotonergic agonists. In fact, the lerisetron- 
Y152 interaction is even more significant than the agonist-Y152 interaction. 
Alignments (figure 4.1) show that residues Y142 and Y152 are missing on 
AChBP. Therefore, the low affinity of lerisetron may be due to the missing 
interactions with Y142 and Y152 on AChBP. Lerisetron binding therefore 
presents an opportunity to improve on the modelling and the understanding of 
the binding site structure. Additionally, if Y142, Y152 and other binding site 
residues interact in a novel way with lerisetron, this could imply possible unique 
uses of lerisetron analogues as 5HT3R-active drugs.
It has been proposed [52] that lerisetron binds 5HT3R in a way that spans 
both the (partial) agonist and antagonist binding site.
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4.4.6 Summary.
The acetylcholine-binding protein (AChBP) has recently been used 
extensively to model the N-terminal binding domains of various cys-loop ligand 
gated ion channels (LGIC’s). There is significant sequence homology among this 
family of ion channels, and between their N-terminal domains and the AChBP. 
However, the pharmacology of the AChBP with respect to many common LGIC 
ligands is not well known. The focus of this work was to obtain data for binding of 
serotonergic ligands to the AChBP, thus checking existing serotonin type 3A 
homopentamer (5-HT3AR) models. We expect a comparison between 5-HT3AR 
binding affinities and AChBP binding affinities to allow evaluation and 
improvement of the binding models, and shed light on important differences 
among members of the LGIC superfamily.
We have used scintillation proximity assay to evaluate the binding of 
serotonin type 3 receptor (5-HT3R) agonists, partial agonists and antagonists on 
the AChBP. These included agonists serotonin (5-HT), A77-chlorophenylbiguanide 
(mCPBG), 2-methyl-serotonin (2-Me-5-HT), and phenylbiguanide (PBG), and 
antagonists lerisetron, tropisetron, granisetron and MDL72222. 5-HT3R 
antagonists ranged from 2-30 times weaker in comparative affinity (Kon AChBP/ 
Ki on 5-HT3R), while agonists for 5-HT3R had 500-30,000 times weaker binding 
to AChBP. Lerisetron was 7000 times weaker in binding AChBP.
Our data confirm the structural similarity of AChBP with 5-HT3R and 
supports the validity of AChBP based antagonist and agonist binding models. 
Particularly, the models of binding proposed by our laboratory (Joshi et al., 2006; 
Suryanarayanan et al., 2005, [22, 23]) are further supported by the binding of 
serotonergic ligands to AChBP.
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Chapter 5: Summary and Future Directions
5.1 Introduction:
In Chapter 1 of this thesis, two hypothesis were proposed: 1) The AChBP 
can be attached to biosensor surfaces and trigger a response that can selectively 
detect the presence and affinity of nicotinic ligands and 2) The AChBP can be 
engineered to selectively recognize different classes of LGIC by mutating key 
binding site amino acids in the AChBP to corresponding amino acids of the target 
LGIC receptor. To test these hypotheses, and initiate development of AChBP 
based biosensor proteins, this thesis addressed the following 7 objectives:
1. Develop an expression and purification scheme for the AChBP that 
permits rapid purification of sufficient quantities of protein.
2 . Determine the storage qualities of the AChBP in solution and identify ways 
of stably storing the protein over a long time period (months).
3. Determine the functionality of the receptor on three biosensor platforms -  
Surface Plasmon Resonance, Scintillation Proximity Assay and 
Microcantilevers.
4. Determine the sensitivity and stability of the AChBP on each of the 
platforms tested in Objective 3.
5. Conduct pharmacological studies of the AChBP to determine the affinity of 
a broad range of LGIC ligands with the AChBP in its native form.
6. Construct point mutations based on predictions from homology modelling 
and ligand studies of the binding domain of the serotonin type 3 receptor, 
which will increase affinity of serotonergic ligand and decrease affinity of 
nicotinic ligands (i.e. Alter the selectivity of the protein to one similar to the 
5 -HT3R.).
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7. Using information obtained as a result of Objective 6, create additional
binding proteins aimed at mimicking selectivity of 5-HT3R subtypes.
Objectives 1-4 were addressed in chapter 3 and objective 5 was 
addressed in chapter 4. Objectives 6 and 7 will be discussed in this chapter and 
constitute future directions of this research.
5.2 Expression and purification of the AChBP.
We chose to express the AChBP in a mammalian expression system and 
engineered the protein for rapid affinity purification using Nickel or Anti-Flag 
affinity chromatography. The preferred method, due to speed and costs was 
Nickel affinity chromatography. Expression in HEK-293 cells was also chosen 
due to cost and efficiency. While both systems were highly effective at producing 
useable AChBP protein, both could be improved given more resources. The 
most reasonable addition to this procedure would be the development of a higher 
capacity expression system. The two best systems would likely be insect cell 
lines or yeast expression. Due to the ease of use and rapid production of a yeast 
expression system, this would likely be the best for producing large quantities of 
protein. However, since different expression systems can produce different 
proteins due to post-translational processing, these systems would likely require 
optimization if implemented. For the studies proposed here, large quantities of 
protein are not necessary and thus the HEK-293 system may remain the most 
productive.
The AChBP purification scheme could also be improved to provide cleaner 
protein. The single column approach yields remarkably pure protein (estimated 
at about 95%) but does contain other cellular proteins. These proteins could be 
eliminated by the use of a second anti-flag affinity column. We have shown in 
SPR studies that the AChBP binds effectively to the anti-Flag chips. This same 
approach can be used to create anti-Flag affinity chromatography columns. A
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Nickel column followed directly by an anti-Flag column should produce protein of 
high purity. While unnecessary for the experiments described in this thesis, pure 
protein would be necessary for biophysical studies including Circular Dichroism 
and x-ray crystallography. Our engineered protein permits this two-step, rapid 
purification. The disadvantages of this approach are the moderately higher costs 
associated with the additional affinity media and anti-Flag antibody. As this 
project moves towards producing new binding proteins (objective 7 above) a 
more pure product will facilitate evaluation of target proteins.
5.3 The AChBP as a biosensor.
Chapter 3 also addressed the question of AChBP functionality as a 
biosensor protein. These studies used 3 different support media and all showed 
advantages and disadvantages inherent in the three platforms. The AChBP, 
however, performed well in all three applications, providing data consistent with 
published literature values and comparable across all three techniques. The 
differences between our data and that of the literature are modest in the 
perspective of the LGIC field, and are explainable by subtle differences in assay 
systems. Differences in between our three assay systems were not statistically 
significant, even though our precision was good. This confirms our hypothesis 
that the AChBP can be an effective biosensor protein. The data obtained in 
chapter 4 demonstrates the use of the AChBP in screening a series of receptor 
ligands.
The microcantilever data in Chapter 3 is particularly interesting since it 
suggests the ability of the microcantilever to detect conformational changes. As 
an allosteric protein, the AChBP undergoes a large conformational change when 
exposed to nicotinic agonists such as acetylcholine and nicotine. This change in 
conformation produces responses on microcantilevers greater than comparable 
antagonists that do not produce conformational changes. The high sensitivity of 
the microcantilevers was likely due to the large conformational change in the
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AChBP protein. This property contributes to the success of the AChBP as a 
biosensor and suggests future proteins based on the AChBP could be equally 
good candidates for microcantilever assays.
5.4 Binding of 5 -HT3R receptor ligands to the AChBP.
Chapter 4 focused on obtaining useful data using one of the AChBP 
methods discussed in chapter 3. The goal of this study was to determine how 
these ligands interacted with the AChBP that has been used as a template in 
computer modelling studies of the 5-HT3R. This is the first data showing how 5- 
HT3R ligands bind to the AChBP and is significant in validating the 5-HT3R 
models.
The outcome of this study is a clear difference in the binding of serotonin 
antagonists and agonists with the AChBP. Our initial analysis of the 5-HT3R 
binding site suggested that, based on the current homology models of the 
receptor, serotonin antagonists should bind with reasonably high affinity. This 
hypothesis is well supported by the data. The granisetron-type antagonists 
bound better than expected with only slightly lower affinities on the AChBP. The 
similarity in binding affinities suggests that the computer models are much more 
likely to produce accurate depictions of the antagonist binding site. Thus this 
study confirms the confidence that many have placed in the quality of these 
models. Future mutagenesis studies (described below in section 5.5) would 
enable the differences between individual models to be explored in more detail. 
Since therapeutically, 5-HT3R antagonists are presently the most important group 
of compounds, this data has a significant impact on drug development. Since the 
homology models are likely to be highly accurate, more confidence can be 
placed in rational drug design approaches.
Analysis of agonist binding models suggested that 5-HT3R agonists would 
be unlikely to bind as tightly to the AChBP as they do to the 5-HT3R itself. This 
hypothesis was also supported by our data. The differences appear to be due to
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the structure of the C-loop. C-loop sequences are dramatically different and are 
likely to produce profound effects on receptor function in addition to ligand 
binding. As discussed in chapter A, the hypothesized movement of the C-loop in 
response to agonist binding is thought to lead to a higher affinity binding site that 
is “capped” by the C-loop. This is thought to be the first step in a two-step 
process that leads to channel opening. Since the AChBP lacks the channel 
regions, this first step does not produce any effect but is necessary for high- 
affinity binding of agonists. The most likely explanation for the weak binding of 
agonists is that they bind but fail to bind well to stabilize the “lid-closed” 
conformation. This is supported by our data showing similar affinities for all 
partial and full agonists on the AChBP. Further studies of the ability of these 
ligands to induce a conformational change could make use of the microcantilever 
sensors. These sensors can detect conformational changes in proteins and are 
likely detecting these changes in the AChBP-modified microcantilevers described 
in chapter 3. Treatment of these microcantilevers with serotonin, mCPBG and 
PBG should produce smaller bending amplitudes when compared to 
acetylcholine or nicotine.
5.5 Future Directions:
This thesis addressed the first 5 of 7 objectives of a larger study. The final 
two objectives require modification of the AChBP based on the data obtained in 
chapters 3 and 4. Objective 6 is intended to produce a 5-HT3R analogue based 
on the AChBP protein using site directed mutagenesis. This project will draw 
heavily on the data obtained in chapter 4 in particular. Objective 7 expands the 
outcome of objective 6 to produce similar binding proteins for GABA, Glycine and 
neuronal nicotinic receptors.
8 6
5.5.1 Developing a 5-HT3R binding protein.
The goal of this future study will be to express AChBP mutants with single 
amino acid substitutions from equivalent positions in the 5-HT3AR sequence, 
which can be synthesized and purified in quantities usable for biosensor 
applications. The next step in this process will be the production of mutant 
AChBP based on molecular modelling and previous site directed mutagenesis 
studies. Table 5.1 lists several primary differences between the 5-HT3R and the 
AChBP at amino acid positions determined to interact with serotonin (see chapter 
4). Several of these positions are conserved, however, some differences exist. 
Where amino acid composition at a specific three dimensional position is 
different, the AChBP amino acid can be mutated to the corresponding 5-HT3R 
amino acid.
Mutations will be initially made singly then in groups based on the results 
of the single mutations. Mutations can be constructed by commercial 
mutagenesis services to facilitate rapid production of mutations, if funding 
permits, or by utilizing inexpensive oligonucleotides and Stratagene's (Cedar 
Creek, TX) QuickChange II site directed mutagenesis kit. Mutant receptors will 
then be expressed and characterized using stably transfected HEK 293 cells in a 
manner similar to that used to produce the wild-type AChBP (chapter 3).
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Table 5.1: Proposed Mutants. The left-hand column shows the corresponding 5-HT3AR amino 
acid, and the right-hand column shows the planned AChBP mutant. * denotes mutants in the 
region of the C-loop: the C-loops of AChBP and 5-HT3AR don’t align well, thus it may be better to 
replace some of these with a C-loop chimera. Note some oligonucleotides have been ordered, 
and we have stably expressed two of the mutants in HEK293 cells (see preliminary data in
supplementary material).
Corresponding 5-HT3AR amino acid, loop AChBP residue/ mutation
W183, loop B None (identical residues)
F226, loop C V183F*
D229, loop C S186D*
S233, loop C A191S
Y234, loop C None (identical residues)
E236, loop C D194E*
E129, loop A N90E
Y143, loop E R104Y
Y153, loop E M114Y
D189, loop B E149D
Entire C loop C-loop chimera
Recombinant proteins will be purified using affinity chromatography 
(Sigma His-select columns, chapter 2) and characterized using immunoblotting 
and SDS-PAGE (denaturing and non-denaturing) analysis. To determine integrity 
of quaternary structure, we will employ gel exclusion analysis and non-denaturing 
PAGE assay. Functional properties will be determined by saturation as well as 
competition ligand binding assays. Mutant binding proteins will initially be 
evaluated by Scintillation Proximity Assay (SPA) or Surface plasmon resonance 
(SPR) then attached to microcantilever surfaces for further testing. SPR will be 
helpful in evaluating the engineered proteins as potential biosensor molecules.
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5.5.2 Development of other LGIC Binding proteins.
Each of the well-known families of cys-loop LGIC’s, GABA type A and C 
(GABAaR, GABAcR), Glycine (GlyR), serotonin type 3 receptors, (5-HT3R), and 
nicotinic acetylcholine receptors (nAChR) have now been modelled based on the 
AChBP [22, 30, 31, 48, 53-57], These models have brought together a 
considerable amount of useful information on binding site structure for the LGIC 
receptor superfamily. A long term goal of the research initiated in this thesis will 
be to develop an equivalent superfamily of binding proteins that can be used in 
place of the membrane bound receptor proteins. The advantages of soluble 
proteins have been discussed earlier but include ease of purification, storage and 
immobilization on biosensor devices. A complete selection of these proteins 
would enable extremely fast evaluation of new drugs but would also permit 
devices designed to detect endogenous ligands in brain or other tissues. To 
obtain these proteins, accurate homology models must be constructed. This 
section describes current receptor models for GABAa, GABAc and Glycine 
receptors that will be the initial targets of future binding protein development.
5.5.2.1 GABAaR Models.
GABAaR are inhibitory chloride channels which are central to the action of 
general anaesthetics, barbiturates, alcohol, and benzodiazepines. AChBP 
{Lymnaea stagna/is, PDB file 119B) was recently used to model the ligand- 
binding domain (LBD) of these LGIC’s [28, 30, 58]. The researchers noted that 
there are an unequal number of amino acids in a few relevant areas of the 
primary sequence of the GABAaR compared to the AChBP; consequently, the 
alignments, and therefore the structural and functional homology is to be viewed 
with caution. The GABAaR receptor LBD sequence allows for a likely “modified 
globulin-like” structure consisting of an N-terminal a-helix followed by ten p- 
strands intercalated by ten loop structures and two short “3-10” helices. Binding 
“loops” (or segments) A-F have been defined [58], as in nAChR and 5-HT3R
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(chapters 1, 4), and again a “+” and face can be defined and are contributed 
by loops A-C and D-F, respectively. As with heteromeric nAChR’s, one subtype 
((3) contributes the “+” face and another (a) contributes the face to the binding 
site (in the nAChR, the a-p naming is the opposite, since the naming of the 
subunits preceded an understanding of the binding sites). Each of the AChBP 
models below verifies this structural information, in addition to providing 
information on the individual binding residues.
The First AChBP GABAaR modelling was performed by in 2002 by 
Cromer et al. [58]. They modelled the most prevalent GABAaR in the human 
brain, the aip2y2 receptor, which data indicate are -(32-a1-p2-a1-y2- hetero- 
pentamers, with GABA-binding sites at the two p2-a1 plus-minus interfaces, and 
a benzodiazepine-binding site at the a1-y2 interface. The binding pocket in this 
model is surrounded by a “box” of aromatic residues, which is similar to the 
aromatic residues said to have cation-Tr interactions with nicotinic agonists in 
nAChR and the quaternary ammonium of N-2-hydroxyethylpiperazine-N9-2- 
ethanesulphonic acid (HEPES) in the AChBP structure [27, 59]. This box 
consists of the aromatic residues (32 F200, Y205 ((32 loop C) Y157 (P2 loop B), 
and F65 (a1 loop D). R67 (a1 loop D), and maybe R132 (a1 loop E) interact with 
the carboxy moiety of GABA. R120 (a1 loop E), surrounding residues such as 
Tyr205, T202, R207, (P2 loop C), and T160 (P2 loop B) may also be important in 
this model, but the authors did not specifically indicate what interactions these 
residues might have. In addition to the LBD, these authors also speculated on 
the benzodiazepine-binding site and the signal transduction mechanism.
Ernst et al. also modelled the GABAAR ligand binding domain [28] based 
on AChBP, and provide a detailed and lucid account of the problems inherent in 
such a model. These researchers preferred the term “comparative” rather than 
homology modelling, based, among other things, on their estimate that only 60- 
75% of GABAAR residues have structural homologues (“equivalents”) in AChBP. 
It seems, therefore that AChBP chimeras, which could incorporate GABA-binding
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sequences, thus increasing homology may be a necessary step in the validation 
of these models.
A GABAaR model was recently made using “quasi-ab-initio” methods for 
modelling the positions of the putative GABA binding loops [30]. The model was 
made to agree with known data: F65, R67, S69 (“loop D”), R120, 1121 (“loop 
E”), R177, V179, V181 and E184 (“loop F”)from the a1 subunit, and Y97, L99 
(“loop” A), Y157, T160 (“loop B”), T202, S204, Y205, R207 and S209 (“loop C”) 
from the 32 subunit are found to be located in the GABA binding pocket.
This could be an oversight, but it seems that GABAaR models have so far 
not had their predictive value tested. It is the opinion of this author that such 
testing could be done easily on AChBP, and with great affect on chimaeric 
AChBP’s (i.e. AChBP-based GABA-binding proteins).
5.5.2.2 GABAcR model.
Modeling of the GABACR, also called the Rho receptor, specifically the p1 
homopentamer, was performed by Harrison et al [31]. Emerging from this study 
is a binding site where tyrosine residues play an important role; when GABA is 
docked to this model, tyrosines from loops D (Y102), E (Y167), B (Y198), and C 
(Y241, Y247) are within 5 A of GABA in energetically favorable orientations. 
Other residues close to GABA are also in the expected binding loops, notably, 
R104 in loop D, S168 (loop E), and S243 (loop C). Three energetically favorable 
orientations are discussed, all of which have Y198, S168, and S243 within 5 A of 
GABA. In the first, the amine group of GABA is directed into a pocket formed by 
loop E (- face), where it hydrogen bonds with two backbone carbonyls (of M156 
and L166), and the hydroxyl of S168; meanwhile the carboxyl group of GABA 
projects toward the C-loop and B-loop of the + face, where it fails to make 
convincing contacts. A, D, and F-loop contacts are absent in the first orientation, 
only two C-loop residues are within 5 A, and the hydrogen bonding capability of 
GABA’s carboxy moiety seems not fully utilized.
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In the second orientation, the GABA molecule is flipped endwise and 
shifted closer to the C-loop and B-loop by 3 A, putting C-loop residue Y241, A- 
loop’s F138, and D-loop’s Y102 within cation-n interaction range of GABA’s 
amine. However, in the E-loop, only S168 is within 5 A of GABA, and with Y198 
(B-loop), is one of the two residues that might hydrogen bond (if weakly) to the 
carboxyl end of GABA. The third orientation, “Harrison orientation 3,” is the 
favorite. The carboxylate end of GABA is close to the basic R104, H105 residues 
of the D-loop, so they would stabilize that group. In loop E, the important S168 
residue oxygen and the backbone of L166 can hydrogen bond with the amine 
group. Finally, important B-loop residue Y198 could make a cation-TT interaction 
with the amine. The C-loop is mostly left out of this model; however the modelers 
did not allow the residues to move upon ligand binding, so there is clearly some 
room to improve the modeling in this flexible area (the authors mention this 
general flaw in their modeling, but don’t relate it specifically to the C-loop).
Interestingly, considered in terms of the theory that the C-loop is largely 
responsible for LGIC subunit specificity, the lack of involvement of the C-loop 
could be key to the differences between the GABAaR and GABAcR relating to 
antagonist binding (bicuculine) and putative lack of desensitization in GABAcR’s. 
Regarding another point more directly relevant to the topic of this thesis, the 
modelers do not seem to consider the fact, in their model, that their template 
AChBP does not bind GABA [3]. Harrison “orientation 3” [31] is consistent with 
that fact, in that AChBP’s D-loop contains no positively charged residues; thus an 
area where an AChBP mutant might be of value. In another possibly key position, 
AChBP’s E-loop M114 aligns with GABAcR S168 -  methionine would not 
effectively hydrogen bond with GABA’s amine. The importance, which the 
modelers of GABA A and C receptors stress, of aromatic residues in the binding 
site, may well be great, but it certainly does not explain why GABA does not bind 
to AChBP, since residues in aromatic positions in GABAaR’s and GABAcR’s are
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either identical residues in AChBP, or are replaced by tryptophan, which should 
be even more effective.
5.5.2.3 GlyR model.
The GlyR a1 homopentamer was modelled using AChBP by Speranskiy et 
al [54], One advantage of this model was that the authors had the foresight to 
use an alignment that utilized the Aplysia as well as Lymnaea AChBP. The 
overall structural conformation of the glycine LBD in this model is similar to the 
AChBP’s LBD. Docking studies were done using the GlyR antagonist strychnine, 
and it was recognised that other docking studies are needed. However, it is 
apparent that strychnine, at least, binds in the usual pocket, more or less deep 
to, and membrane-side of, the C-loop (naming of the loops in this paper follows 
Brejc et al’s AChBP naming [27] and can be compared using figure 4.1 of 
chapter 4). Several C-loop residues are close to strychnine, as well as two E- 
loop residues and an F-loop residue. Instead of B-loop residues being involved 
as with other cys-loop LGIC’s, two residues membrane-side of the A-loop appear 
close to strychnine. Specific interactions are not explored. It should be noted 
that strychnine is much larger than glycine, and thus may not relate in the same 
way to the flexible C-loop; for instance, the antagonist could act more by blocking 
entry into, rather than occupying the agonist-binding site. Mutations to the 
AChBP, as well as comparative studies of the GlyR-related pharmacology of the 
two AChBP’s should again be useful here; however, more modelling and/or 
docking studies will be needed in order to make progress.
5.6. Further Pharmacological testing of AChBP.
GABA type A and Glycine (GlyR) receptors have recently been modelled 
based, in part, on the AChBP (section 5.5). However, with the exception of GABA 
and glycine themselves, which did not bind to the AChBP, none of the ligands 
associated with these receptors have been characterized with respect to their
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binding to AChBP. Besides these models, several models of both homo- and 
heteromeric nAChR’s and 5-HT3R’s depend on AChBP. A broad range of 
nAChR compounds and now several 5-HT3R ligands (see chapter 4) have been 
tested on AChBP, which have already added to the validity of those models. 
However, there is potential to learn more about sites other than the primary 
binding sites for these receptors from the AChBP. Thus, in addition to GABAR 
and GlyR ligands, nAChR allosteric ligands also need to be studied using the 
AChBP. Table 5.2 shows some compounds which should be tested on AChBP in 
order to further characterize AChBP’s pharmacology.
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Table 5.2. Compounds to be tested on AChBP. By no means is this a complete list. Tropisetron 
is a GlyR potentiator [2], and it would be interesting to know why, and if the binding site is the 
same as on AChBP.
Compounds that should be 
tested on AChBP
Peptides SLURP1, SLURP2, galanin 
gephyrin
Heavy metals
nAChR potentiators azieomidate, etomidate, 
phencyclidine
Divalent cations of Ca, Zn, 
Cu, Cd, Ni, Mn, Co
Barbiturates Thiopental, MPPB, TID, 
barbital, pento-, amyl-, seco-, 
and iso- barbital,
Act on nAChR’s as well as 
GABAaR’s and likely others
SSRI’s Flouxetine
TCA’s Imipramine
SNRI’s and NSRI’s Venlaflaxine
So called non-competitive 
nAChR antagonists
Quinacrine, Tetracaine, 
dizocilpine, phencyclidine, 
ketamine
Allosteric nAChR 
modulators
Galanthamine, Physostigmine, 
dFBr and analogues, 
ryanodine
Tabacco alkaloids, nicotine 
metabolites
See Arneric and Brioni, 1999, 
pg 214-218
GABAaR competitive 
antagonists
Bicuculine, gabazine,
GABAaR competitive 
agonists
Muscimol
Benzodiazpines Flunitrazapam, diazepam. 
Zolpidem
Classic GABAaR allosteric 
modulators
GABAcR agonist/ partial 
agonist and antagonist 
ligands
3-APMPA, TPMPA, Imidazole-
4-acetic acid, picrotoxin, 
CACA, TACA, isoguvacine
Neurosteriods THPROG, pregnalone, 
dehydropiandrosterone
Anaesthetics Act on GABA, other receptors
Ginko biloba compounds Act on glycine receptors
GlyR potentiators Ethanol, and other n-alcohols, 
propofol, *
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5.7. General Summary.
Ligand-Gated Ion Channels like the serotonin 5-HT3R are involved in a 
wide range of physiological processes including nerve conduction, regulation of 
blood flow, fluid balance and gastric motility. In the central nervous system, 
these important proteins mediate fast excitatory and inhibitory neurotransmission. 
The construction of a serotonin binding protein would enable the development of 
a molecular biosensor for serotonin. Chapter 3 explored the potential of the 
AChBP as a biosensor, and chapter 4 establishes a baseline from which to 
evaluate serotonergic AChBP mutants. Although the project has not yet reached 
the point of a viable serotonin biosensor, the previous chapters lay the 
groundwork for future studies as described in section 5.5 above.
This project is highly significant and contributes to human health. In 
addition to drug development applications sensors of this type could be used for 
in-vivo, in-vitro and environmental biosensor applications. The data presented in 
this thesis provide a firm foundation on which to build a family of biosensor 
proteins covering the spectrum of LGIC receptors.
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